[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 86 of about 86
1. Charalambous S, Mylonaki E, Fotas A, Papatsoris AG, Papathanasiou A, Triantafyllidis A, Rombis V, Touloupidis S: Large adrenal metastasis in non-small cell lung carcinoma. Case report and literature review. Tumori; 2008 Jan-Feb;94(1):134-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large adrenal metastasis in non-small cell lung carcinoma. Case report and literature review.
  • Adrenal metastases are frequent in patients with non-small cell lung carcinoma (NSCLC).
  • We present a case of a large adrenal metastasis from NSCLC and we discuss the relevant literature.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18468350.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


2. Zografos GN, Farfaras A, Aggeli C, Kontogeorgos G, Pagoni M, Vogiati S, Vasiliadis G, Papastratis G: Laparoscopic adrenalectomy for large adrenal metastasis from contralateral renal cell carcinoma. JSLS; 2007 Apr-Jun;11(2):261-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic adrenalectomy for large adrenal metastasis from contralateral renal cell carcinoma.
  • We present herein the case of a patient with solitary metachronous contralateral adrenal metastasis from renal cell cancer.
  • Histology showed right adrenal metastasis from renal cancer.

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1983 Apr;21(4):403-5 [6836834.001]
  • [Cites] J Urol. 1982 Jun;127(6):1092-5 [7087014.001]
  • [Cites] Semin Nephrol. 1987 Jun;7(2):131-9 [3306862.001]
  • [Cites] Urology. 1991 Oct;38(4):364-8 [1755149.001]
  • [Cites] J Surg Oncol. 1992 Jan;49(1):45-8 [1548881.001]
  • [Cites] Br J Urol. 1995 Apr;75(4):445-7 [7788253.001]
  • [Cites] J Urol. 1997 Apr;157(4):1217-22 [9120905.001]
  • [Cites] Eur Radiol. 1997;7(4):557-8 [9204340.001]
  • [Cites] J Urol. 1997 Dec;158(6):2227 [9366350.001]
  • [Cites] Cancer. 1998 Jan 15;82(2):389-94 [9445197.001]
  • [Cites] Urology. 1998 Apr;51(4):539-43 [9586603.001]
  • [Cites] Semin Surg Oncol. 1999 Jun;16(4):293-306 [10332775.001]
  • [Cites] BJU Int. 2004 Nov;94(7):1026-9 [15541121.001]
  • [Cites] J Urol. 2005 Feb;173(2):519-25 [15643237.001]
  • [Cites] Eur J Cardiothorac Surg. 2005 May;27(5):753-6 [15848309.001]
  • [Cites] Hormones (Athens). 2006 Jan-Mar;5(1):52-6 [16728385.001]
  • [Cites] Urology. 2000 Aug 1;56(2):211-5 [10925080.001]
  • [Cites] J Urol. 2000 Nov;164(5):1505-8 [11025692.001]
  • [Cites] World J Surg. 2001 Jul;25(7):905-13 [11572032.001]
  • [Cites] Arch Surg. 2002 Aug;137(8):948-51; discussion 952-3 [12146996.001]
  • [Cites] Laryngoscope. 2002 Mar;112(3):453-6 [12148853.001]
  • [Cites] Urol Nefrol (Mosk). 1999 Mar-Apr;(2):51-2 [12434447.001]
  • [Cites] J Urol. 2003 Jan;169(1):71-4 [12478106.001]
  • [Cites] Surg Today. 2004;34(3):272-5 [14999544.001]
  • [Cites] Minerva Chir. 2004 Feb;59(1):1-5 [15111826.001]
  • [Cites] J Urol. 1967 Jun;97(6):978-82 [6028330.001]
  • [Cites] Cancer. 1971 Nov;28(5):1165-77 [5125665.001]
  • [Cites] Cancer. 1970 Jan;25(1):26-40 [5410313.001]
  • [Cites] JAMA. 1969 Jan 13;207(2):322-8 [5818154.001]
  • [Cites] J Urol. 1972 May;107(5):705-10 [5022527.001]
  • [Cites] J Urol. 1975 Dec;114(6):836-8 [1195458.001]
  • [Cites] J Urol. 1978 Nov;120(5):540-2 [712892.001]
  • [Cites] Semin Oncol. 1983 Dec;10(4):390-400 [6665566.001]
  • (PMID = 17761094.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3015724
  •  go-up   go-down


3. Yokoyama H, Tanaka M: Incidence of adrenal involvement and assessing adrenal function in patients with renal cell carcinoma: is ipsilateral adrenalectomy indispensable during radical nephrectomy? BJU Int; 2005 Mar;95(4):526-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of adrenal involvement and assessing adrenal function in patients with renal cell carcinoma: is ipsilateral adrenalectomy indispensable during radical nephrectomy?
  • OBJECTIVE: To determine the value of ipsilateral adrenalectomy with radical nephrectomy, by investigating the clinical aspects of adrenal involvement and adrenocortical function in patients with renal cell carcinoma (RCC).
  • PATIENTS AND METHODS: The demographic, clinical and pathological data of adrenal involvement were reviewed in 247 patients with RCC.
  • To evaluate adrenocortical function, 14 patients (adrenalectomy in eight, adrenal-sparing in six) had a rapid adrenocorticotropic hormone (ACTH) stimulation test before and 2 weeks after surgery.
  • RESULTS: There was adrenal involvement with RCC in seven of the 247 (2.8%) patients (a solitary adrenal metastatic tumour in four and direct extension into the adrenal gland in three).
  • All adrenal involvement was detectable on abdominal computed tomography before surgery, and these patients had a large primary renal tumour of > pT2 and/or distant metastasis.
  • Plasma cortisol levels declined significantly more in response to the rapid ACTH stimulation test in those treated by adrenalectomy than in those with spared adrenal glands at 2 weeks after surgery (P < 0.05), while there was no significant difference between the groups before surgery.
  • CONCLUSIONS: These results suggest that unconditional ipsilateral adrenalectomy with radical nephrectomy for RCC should be avoidable, and thus preserve the reserve of adrenocortical function, as preoperative imaging, especially thin-slice multidetector helical computed tomography, can detect adrenal involvement with RCC in most cases.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Nephrectomy / methods


Advertisement
4. Matsuoka T, Morikage N, Kuga T, Nakayama T, Fujii Y: [Metastatic carcinoma of the adrenal gland from large cell neuroendocrine carcinoma; report of a case]. Kyobu Geka; 2005 Jun;58(6):499-503
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic carcinoma of the adrenal gland from large cell neuroendocrine carcinoma; report of a case].
  • A 69-year-old man had undertaken left upper lobectomy (ND 2 a) with partial resection of the left lower lobe under the diagnosis of a primary lung cancer, T2N0M0, stage IB in June, 2002.
  • The histopathological diagnosis was large cell neuroendocrine carcinoma (LCNEC), T3N0M0, stage IIB.
  • Abdominal computed tomography (CT) revealed an enhanced tumor in the left adrenal lesion, 3 cm in diameter, in October, 2003.
  • Although a prognosis of LCNEC is poor in general, we should consider the resection of metastatic carcinoma of the adrenal gland from LCNEC for long-term survival expectantly.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / secondary. Carcinoma, Neuroendocrine / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15957427.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Izbizky G, Elias D, Gallo A, Farias P, Sod R: Prenatal diagnosis of fetal bilateral adrenal carcinoma. Ultrasound Obstet Gynecol; 2005 Nov;26(6):669-71
MedlinePlus Health Information. consumer health - Fetal Health and Development.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prenatal diagnosis of fetal bilateral adrenal carcinoma.
  • Most of the large abdominal masses detected antenatally are renal in origin, although adrenal tumors should also be kept in mind in their differential diagnosis.
  • We report a case of a large-for-gestational-age fetus with abdominal distention secondary to bilateral adrenal carcinoma, polyhydramnios and placental enlargement.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Beckwith-Wiedemann Syndrome / pathology. Fetal Diseases / pathology
  • [MeSH-minor] Abortion, Spontaneous. Adenoma, Islet Cell / pathology. Adult. Diagnosis, Differential. Fatal Outcome. Female. Gestational Age. Humans. Infant, Newborn. Neoplasm Metastasis / pathology. Pancreatic Neoplasms / pathology. Pregnancy. Ultrasonography, Doppler, Color. Ultrasonography, Prenatal / methods

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 ISUOG
  • (PMID = 16254889.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Ito K, Mizuguchi Y, Sato A, Kuroda K, Horiguchi A, Kimura F, Sumitomo M, Asano T, Hayakawa M: [Clinical evaluation for adrenal metastasis of renal cell carcinoma in a single institute]. Nihon Hinyokika Gakkai Zasshi; 2008 May;99(4):584-92
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical evaluation for adrenal metastasis of renal cell carcinoma in a single institute].
  • OBJECTIVE: Clinicopathogical features and prognosis of patients with renal cell carcinoma (RCC) concomitant with adrenal involvement (metastasis or invasion) were evaluated in a single institute.
  • METHODS: In 380 patients with RCC who underwent radical nephrectomy 18 patients had adrenal involvement (13 ipsilateral adrenal involvement).
  • RESULTS: Patients with ipsilateral adrenal involvement had significantly higher percentage of tumor>5.5 cm, upper pole tumor, pathological stage (pT) 3< or =, lymph node metastasis, distant metastasis outside ipsilateral adrenal gland, histological grade 3 and microvascular invasion than control patients (p<0.05).
  • Therefore, large tumor (especially 5.5 cm<), upper pole tumor, clinical T3 (especially patients with tumor thrombus), lymph node metastasis and distant metastasis were candidates for risk factors of ipsilateral adrenal involvement.
  • 76.9% of ipsilateral adrenal metastasis could be diagnosed by computed tomography (CT).
  • Thus, preoperative adrenal finding by CT is very important to determine the indication of ipsilateral adrenalectomy.
  • All 3 patients with small ipsilateral adrenal metastasis that could not be detected preoperative CT died within one and half year postoperatively.
  • Patients with solitary adrenal metastasis appeared to have better prognosis compared to those with both adrenal and other metastases.
  • In 4 patients who survived more than 2 years after the presentation of adrenal metastasis, 3 patients had solitary adrenal metastasis and underwent adrenalectomy.
  • CONCLUSION: From the results in a single institute, radiological finding of adrenal grand, tumor size, tumor location, T stage, lymph node metastasis and distant metastasis outside ipsilateral adrenal gland are possible important factors to determine the indication of ipsilateral adrenalectomy preoperatively.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18536308.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Moslemi MK, Al-Mousawi S, Dehghani Firoozabadi MH: Renal cell carcinoma mimicking adrenal tumor. J Oncol; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma mimicking adrenal tumor.
  • There are a variety of causes of adrenal pseudotumors on computerized tomography (CT) scan, including upper-pole renal mass, gastric diverticulum, prominent splenic lobulation, pancreatic mass, hepatic mass, and periadrenal varices.
  • We present a case of a large subhepatic mass that discrimination of its origin from neighborhood organs was difficult preoperatively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20847950.001).
  • [ISSN] 1687-8469
  • [Journal-full-title] Journal of oncology
  • [ISO-abbreviation] J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2934774
  •  go-up   go-down


8. Zhang L, Talwalkar SS, Shaheen SP 2nd: A case of primary unilateral adrenal Burkitt-like large cell lymphoma presenting as adrenal insufficiency. Ann Diagn Pathol; 2007 Apr;11(2):127-31
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary unilateral adrenal Burkitt-like large cell lymphoma presenting as adrenal insufficiency.
  • Primary adrenal lymphoma is extraordinarily rare, in comparison with secondary adrenal involvement by non-Hodgkin lymphoma.
  • Although higher-resolution imaging techniques have enhanced detection of adrenal masses, biopsy or excision is often needed for definitive diagnosis.
  • Percutaneous computed tomography-guided fine needle aspiration has great diagnostic value in the workup of adrenal masses, but is limited by sampling error and artifacts.
  • Primary adrenal lymphoma most commonly manifests with diffuse large B-cell morphology.
  • Burkitt-like large cell lymphoma morphology has been previously reported only once, to our knowledge.
  • We report an 80-year-old man presenting with unilateral primary adrenal lymphoma showing Burkitt-like morphology and adrenal insufficiency.
  • Fine needle aspiration yielded a dispersed population of monomorphic, medium to large cells suggestive of lymphoma.
  • Although dispersed cell populations cytologically favor lymphoma, metastatic poorly differentiated carcinoma and adrenal cortical carcinoma can manifest similarly.
  • Integrated histological, immunohistochemical, and flow cytometric immunophenotyping would provide an accurate and definitive diagnosis.
  • We review the literature and discuss important issues with regard to diagnosis.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Insufficiency / pathology. Burkitt Lymphoma / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349573.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


9. von Knobloch R, Schrader AJ, Walthers EM, Hofmann R: Simultaneous adrenalectomy during radical nephrectomy for renal cell carcinoma will not cure patients with adrenal metastasis. Urology; 2009 Feb;73(2):333-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous adrenalectomy during radical nephrectomy for renal cell carcinoma will not cure patients with adrenal metastasis.
  • OBJECTIVES: To present data from all patients with adrenal involvement after prolonged follow-up and to revise our advice given in 1999.
  • In 1999, we published our results for a large series of patients with adrenal metastasis from renal cell carcinoma.
  • METHODS: The charts of 617 patients who had undergone radical nephrectomy with simultaneous adrenalectomy for renal cell carcinoma at the Department of Urology, Philipps-University Medical School, Marburg from 1985 to 1999 were retrospectively reviewed.
  • In 1999, 23 of 617 patients (3.7%) were found to have adrenal metastasis.
  • The 23 patients included 16 with unilateral ipsilateral adrenal metastasis only, 1 with unilateral contralateral metastasis, and 6 with bilateral adrenal involvement.
  • CONCLUSIONS: With these data available, we are now aware that we cannot cure patients with adrenal metastasis by incorporating simultaneous ipsilateral adrenalectomy into routine radical nephrectomy for renal cell carcinoma.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Nephrectomy / methods

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19038420.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Buurman H, Saeger W: Abnormalities in incidentally removed adrenal glands. Endocr Pathol; 2006;17(3):277-82
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormalities in incidentally removed adrenal glands.
  • The incidence and type of pathological findings in a large group of surgically removed adrenal glands were analyzed: 282 resected adrenals from the years 1995 to 2004 were examined; 242 adrenals were removed for therapy of renal cell carcinomas (in one case both adrenals were removed).
  • Other indications for adrenalectomies were malignant tumors (urothelial carcinoma, squamous cell carcinoma, sarcoma, lymphoma, etc.) and benign findings (oncocytoma, angiomyolipoma, pyelonephritis, etc.).
  • A total of 18 adrenals exhibited a metastasis or diffuse infiltration of the adrenal or para-adrenal tissue by a malignant tumor (17 renal cell carcinomas, 1 non-Hodgkin's lymphoma).
  • Eighty-nine adrenal hyperplasias were diagnosed.
  • The adrenals exhibited infiltration or metastasis by malignant tumors (6.4%), adrenal adenomas (2.5%), adrenal hyperplasias (31.6%), and other alterations (38.7%).
  • [MeSH-major] Adrenal Gland Neoplasms / epidemiology. Adrenal Gland Neoplasms / pathology. Adrenal Glands / pathology. Incidental Findings
  • [MeSH-minor] Adrenalectomy. Adult. Aged. Aged, 80 and over. Carcinoma, Renal Cell / surgery. Female. Humans. Kidney Neoplasms / surgery. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17308364.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Rosenblatt GS, Takesita K, Fuchs GJ, Colquhoun SD, Ng CS: Adrenal metastasis with inferior vena cava tumor thrombus through adrenal vein. Urology; 2009 Aug;74(2):290-1
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal metastasis with inferior vena cava tumor thrombus through adrenal vein.
  • Abdominal ultrasonography showed a large right renal mass.
  • Magnetic resonance imaging revealed a 12-cm renal mass and a separate 7.5-cm ipsilateral adrenal mass, with a tumor thrombus extending through the adrenal vein and into the inferior vena cava.
  • Right radical nephrectomy/adrenalectomy with caval tumor thrombectomy was performed, and both lesions were diagnosed as renal cell carcinoma.
  • We report on an unusual case of a large renal cell carcinoma with metastasis to the adrenal gland and vena caval extension by way of the adrenal venous system, without renal vein thrombus.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Glands / blood supply. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Neoplastic Cells, Circulating / pathology. Vena Cava, Inferior / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19501878.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Brauckhoff M, Dralle H: [Recurrent operations on the adrenal glands]. Chirurg; 2005 Mar;76(3):227-37
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent operations on the adrenal glands].
  • Repeat adrenalectomy may be required due to ipsilateral recurrence of benign or malignant adrenal tumors after previous total or subtotal adrenalectomy.
  • Even for multivisceral resection in patients with adrenocortical carcinoma, complete resection of local recurrent tumor offers results similar to those of primary resection (5-year survival 40-60%).
  • The effect of endoscopic adrenalectomy in patients with large tumors (>5 cm) or suspected malignancy has still not been well examined.
  • In any case, during open or endoscopic approach, tumor spillage must be avoided to prevent local tumor cell implantation.
  • Following subtotal adrenalectomy, the risk of ipsilateral recurrence correlates with disease, follow-up, localization, size of the adrenal remnant, and, in case of familial pheochromocytoma, probably with genotype.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Adrenocortical Carcinoma / surgery. Neoplasm Recurrence, Local / surgery. Pheochromocytoma / surgery
  • [MeSH-minor] 3-Iodobenzylguanidine / therapeutic use. Adult. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Mitotane / therapeutic use. Octreotide / therapeutic use. Palliative Care. Paraneoplastic Endocrine Syndromes / diagnosis. Paraneoplastic Endocrine Syndromes / mortality. Paraneoplastic Endocrine Syndromes / surgery. Radiotherapy, Adjuvant. Reoperation

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endourol. 1999 Mar;13(2):99-104; discussion 104-6 [10213103.001]
  • [Cites] Arch Surg. 2001 May;136(5):543-9 [11343545.001]
  • [Cites] Surgery. 2001 Dec;130(6):1072-7 [11742341.001]
  • [Cites] Ann Thorac Surg. 1996 Jan;61(1):222-4 [8561564.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1043-7 [12045859.001]
  • [Cites] Eur J Surg. 1999 May;165(5):431-5 [10391158.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):325-9 [1973322.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1347-52 [11038205.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1323-9 [15517476.001]
  • [Cites] World J Surg. 2000 Jan;24(1):108-13 [10594213.001]
  • [Cites] Surgery. 1992 Dec;112(6):963-70; discussion 970-1 [1455321.001]
  • [Cites] Eur J Endocrinol. 2004 Jun;150(6):789-92 [15191348.001]
  • [Cites] Surgery. 2003 Dec;134(6):1020-7; discussion 1027-8 [14668736.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1005-12 [12045858.001]
  • [Cites] World J Surg. 1998 Jun;22(6):621-6; discussion 626-7 [9597938.001]
  • [Cites] N Engl J Med. 1977 Jun 2;296(22):1269-71 [859517.001]
  • [Cites] Endocr J. 2002 Apr;49(2):227-9 [12081243.001]
  • [Cites] Surgery. 1995 Dec;118(6):1090-8 [7491528.001]
  • [Cites] Urology. 1999 Apr;53(4):679-83 [10197840.001]
  • [Cites] Horm Res. 2002;57(5-6):197-9 [12053093.001]
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] Surg Today. 2004;34(3):251-5 [14999539.001]
  • [Cites] Surgery. 1985 Jan;97(1):16-20 [3966225.001]
  • [Cites] Surgery. 2000 Dec;128(6):1007-11;discussion 1011-2 [11114636.001]
  • [Cites] Endocr Rev. 2001 Feb;22(1):75-110 [11159817.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):719-26 [10622498.001]
  • [Cites] Chirurg. 2003 May;74(5):473-7 [12748796.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):330-4 [2368435.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):5-7 [10634355.001]
  • [Cites] J Am Coll Surg. 2004 Apr;198(4):525-34; discussion 534-5 [15051000.001]
  • [Cites] J Pediatr Surg. 1993 Oct;28(10):1248-51; discussion 1251-2 [8263682.001]
  • [Cites] J Intern Med. 1995 Oct;238(4):363-7 [7595173.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Nov;69(5):1078-81 [2793991.001]
  • [Cites] Eur J Surg. 1999 Jun;165(6):535-8 [10433135.001]
  • [Cites] Surgery. 2003 Dec;134(6):956-62; discussion 962-3 [14668728.001]
  • [Cites] Surgery. 1996 Dec;120(6):1064-70; discussion 1070-1 [8957496.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Jan;46(1):39-44 [9059556.001]
  • [Cites] World J Surg. 1992 Jul-Aug;16(4):753-8 [1413845.001]
  • [Cites] Surgery. 2002 Dec;132(6):1008-11; discussion 1012 [12490848.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2004 Aug;14(4):234-5 [15345163.001]
  • [Cites] J Urol. 1997 Jun;157(6):2239 [9146626.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5367-84 [12466322.001]
  • [Cites] J Urol. 1999 Feb;161(2):395-8 [9915410.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4083-7 [12970267.001]
  • [Cites] J Urol. 2000 Jul;164(1):14-7 [10840414.001]
  • [Cites] Arch Surg. 2002 Jun;137(6):682-8; discussion 688-9 [12049539.001]
  • [Cites] World J Surg. 1982 Jul;6(4):397-402 [7123976.001]
  • [Cites] World J Surg. 1984 Aug;8(4):612-21 [6148811.001]
  • [Cites] Surgery. 1997 Dec;122(6):1068-73; discussion 1073-4 [9426421.001]
  • [Cites] ANZ J Surg. 2003 Aug;73(8):664-6 [12887546.001]
  • [Cites] Horm Res. 1999;52(2):97-100 [10681640.001]
  • [Cites] Eur Urol. 2000 Sep;38(3):344-8 [10940711.001]
  • [Cites] Minn Med. 1974 Dec;57(12):951-2 [4424014.001]
  • [Cites] Eur J Endocrinol. 2004 Jul;151(1):15-27 [15248818.001]
  • [Cites] J Endourol. 2002 Apr;16(3):171-4 [12028627.001]
  • [Cites] Chirurg. 1989 Apr;60(4):266-71; discussion 271-2 [2566455.001]
  • [Cites] Arch Surg. 1974 Apr;108(4):450-4 [4815920.001]
  • [Cites] Front Horm Res. 2004;31:155-62 [14674310.001]
  • [Cites] Surgery. 1997 Dec;122(6):1212-8 [9426440.001]
  • [Cites] Br J Surg. 1999 Jan;86(1):94-7 [10027369.001]
  • [Cites] J Urol. 1998 Aug;160(2):330-4 [9679871.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Mar;60(3):273-87 [15008991.001]
  • [Cites] Surgery. 1983 Dec;94(6):938-40 [6648808.001]
  • [Cites] Henry Ford Hosp Med J. 1987;35(2-3):127-8 [2891644.001]
  • (PMID = 15739057.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 35MRW7B4AD / 3-Iodobenzylguanidine; 78E4J5IB5J / Mitotane; RWM8CCW8GP / Octreotide
  • [Number-of-references] 45
  •  go-up   go-down


13. Ohtake H, Kawamura H, Matsuzaki M, Yokoyama E, Kitajima M, Onizuka S, Yamakawa M: Oncocytic adrenocortical carcinoma. Ann Diagn Pathol; 2010 Jun;14(3):204-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic adrenocortical carcinoma.
  • Only 17 cases of oncocytic adrenocortical carcinoma have been reported in the English literature.
  • Here, we report an incidental case of oncocytic adrenocortical carcinoma.
  • Abdominal computed tomography revealed a left adrenal tumor.
  • Large polygonal tumor cells were arranged in a generally diffuse architecture and exhibited abundant eosinophilic granular cytoplasm.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology
  • [MeSH-minor] Aged. Autoantibodies / analysis. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cell Nucleus / pathology. Humans. Incidental Findings. Male. Mitochondria / immunology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20471567.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor
  •  go-up   go-down


14. Yener S, Ertilav S, Secil M, Akinci B, Demir T, Comlekci A, Yesil S: Natural course of benign adrenal incidentalomas in subjects with extra-adrenal malignancy. Endocrine; 2009 Aug;36(1):135-40
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural course of benign adrenal incidentalomas in subjects with extra-adrenal malignancy.
  • Patients with extra-adrenal malignancies are diagnosed increasingly with benign adrenal tumors, as well as non-oncology subjects.
  • We aimed to demonstrate the natural course of adrenal adenomas in terms of mass size and hormonal status in oncology and non-oncology subjects.
  • We also compared the characteristics and behavior of adrenal adenomas with adrenal malignancies.
  • In our registry of adrenal tumors (n = 335), we prospectively evaluated 29 oncology subjects (EAM+) and age, gender, and follow-up duration matched 110 non-oncology subjects (EAM-) with adrenal adenomas.
  • We also included 16 subjects with adrenal malignancies (primary; 3 and metastasis; 13).
  • Subjects with malignant adrenal tumors were older (P = 0.06), had larger tumors at presentation (P < 0.001), and showed mass enlargement during a shorter follow-up duration (P < 0.001).
  • Oncology subjects with adrenal adenomas featured similar baseline and follow-up parameters in terms of mass enlargement and development of subclinical Cushing Syndrome when compared with non-oncology subjects.
  • Malignant adrenal tumors were characterized with large, rapidly growing tumors of older ages.
  • Conservative approach can be suggested to oncology subjects for adrenal adenomas unless clinical and radiological suspicion of adrenal malignancy is present.
  • [MeSH-major] Adenoma / epidemiology. Adrenal Cortex Neoplasms / epidemiology. Cushing Syndrome / epidemiology. Neoplasms / epidemiology. Pheochromocytoma / epidemiology
  • [MeSH-minor] Adult. Aged. Carcinoma, Non-Small-Cell Lung / epidemiology. Carcinoma, Renal Cell / epidemiology. Disease Progression. Female. Follow-Up Studies. Humans. Incidental Findings. Kidney Neoplasms / epidemiology. Lung Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Male. Middle Aged. Pancreatic Neoplasms / epidemiology. Prevalence. Registries

  • MedlinePlus Health Information. consumer health - Benign Tumors.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19381885.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Tanaka T, Sekimura A, Tanaka H, Tonegawa K, Ogawa K, Haneda H: [Gallbladder metastasis of large cell lung cancer]. Kyobu Geka; 2009 Nov;62(12):1069-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gallbladder metastasis of large cell lung cancer].
  • A man, who received right upper lobectomy of the lung due to stage IIB large cell carcinoma 7 and half years ago, visited our hospital complaining of right upper abdominal pain.
  • Pathological diagnosis was adenosquamous cell carcinoma After 1 year and 4 months later, left adrenal gland tumor was found by CT scan, and the surgery was conducted.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Gallbladder Neoplasms / secondary. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19894573.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Coli A, Di Giorgio A, Castri F, Destito C, Marin AW, Bigotti G: Sarcomatoid carcinoma of the adrenal gland: A case report and review of literature. Pathol Res Pract; 2010 Jan 15;206(1):59-65
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid carcinoma of the adrenal gland: A case report and review of literature.
  • Herein, we report a case of sarcomatoid carcinoma of the adrenal gland in a 75-year-old woman who presented with left abdominal pain of one month's standing.
  • The results of abdominal ultrasonography and computed tomography (CT) showed the presence of a large heterogeneous adrenal mass.
  • Histologically, the neoplasm showed areas of adrenocortical carcinoma and areas of sarcomatoid spindle cell proliferation.
  • To the best of our knowledge, only seven cases of adrenal sarcomatoid carcinoma have been reported in the medical literature.
  • We review the reported cases according to the 2004 classification of the World Health Organization (WHO) of lung tumors, and highlight the histogenesis, diagnosis, and clinical course of this very aggressive tumor.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Carcinosarcoma / secondary. Liver Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19369012.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 16
  •  go-up   go-down


17. Ciancio G, Vaidya A, Shirodkar S, Manoharan M, Hakky T, Soloway M: En bloc mobilization of the pancreas and spleen to facilitate resection of large tumors, primarily renal and adrenal, in the left upper quadrant of the abdomen: techniques derived from multivisceral transplantation. Eur Urol; 2009 May;55(5):1106-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] En bloc mobilization of the pancreas and spleen to facilitate resection of large tumors, primarily renal and adrenal, in the left upper quadrant of the abdomen: techniques derived from multivisceral transplantation.
  • When these lesions are large, safely resecting them often presents a significant technical challenge, with the possibility of resultant morbidity and mortality.
  • Pathology included malignant and benign lesions, including renal cell carcinoma (RCC) with or without inferior vena cava (IVC) involvement, adrenal tumors, retrocrural lymphadenopathy from testicular cancer, and transitional cell carcinoma of the renal pelvis.
  • SURGICAL PROCEDURE: An extended subcostal transabdominal approach was used to resect large tumors in the left upper abdomen.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Dissection / methods. Kidney Neoplasms / surgery. Organ Transplantation. Vascular Neoplasms / surgery
  • [MeSH-minor] Abdominal Cavity / surgery. Adrenalectomy / methods. Adult. Aged. Aged, 80 and over. Blood Loss, Surgical. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Monitoring, Intraoperative / methods. Neoplasm Invasiveness / pathology. Neoplasm Staging. Nephrectomy / methods. Pancreas / anatomy & histology. Postoperative Complications / prevention & control. Retrospective Studies. Risk Assessment. Spleen / anatomy & histology. Stomach / anatomy & histology. Treatment Outcome. Tumor Burden. Vena Cava, Inferior. Young Adult


18. Gounaris I, Rahamim J, Shivasankar S, Earl S, Lyons B, Yiannakis D: Marked response to a cisplatin/docetaxel/temozolomide combination in a heavily pretreated patient with metastatic large cell neuroendocrine lung carcinoma. Anticancer Drugs; 2007 Nov;18(10):1227-30
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marked response to a cisplatin/docetaxel/temozolomide combination in a heavily pretreated patient with metastatic large cell neuroendocrine lung carcinoma.
  • At present, there is no clear consensus on the most appropriate treatment approach for large cell neuroendocrine carcinoma of the lung.
  • Large cell neuroendocrine carcinoma lesions differ from other nonsmall cell lung carcinomas in that they have a particularly aggressive clinical behaviour and extremely poor prognosis.
  • We report a 52-year-old woman large cell neuroendocrine carcinoma patient with progressive stage IV disease in the chest, liver, adrenal glands and, particularly, the brain, who achieved a marked response to a fourth-line combination of docetaxel, cisplatin and temozolomide.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / drug therapy. Carcinoma, Neuroendocrine / drug therapy. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17893525.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Sugiura Y, Kaseda S, Kakizaki T, Takeuchi K, Iizuka Y, Nakamura N: [Tonsillar metastais from primary lung large cell neuroendocrine carcinoma in the early stage; report of a case]. Kyobu Geka; 2009 Nov;62(12):1101-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tonsillar metastais from primary lung large cell neuroendocrine carcinoma in the early stage; report of a case].
  • We experienced an extremely rare case of large cell neuroendocrine carcinoma (LCNEC) of the lung metastasizing to the tonsil.
  • The pathological diagnosis was stage IA LCNEC of the lung.
  • In addition, metastases to the liver, lymphnode of abdomen, left adrenal and bone followed in 1 month.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Lung Neoplasms / pathology. Tonsillar Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19894580.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Iwanami T, Uramoto H, Baba T, Takenaka M, Yokoyama E, Oka S, So T, Ono K, So T, Takenoyama M, Hanagiri T, Iwata T, Inoue M, Yasumoto K: [Treatment recommendations for adrenal metastasis of non-small cell lung cancer]. Kyobu Geka; 2010 Dec;63(13):1101-6; discussion 1106-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment recommendations for adrenal metastasis of non-small cell lung cancer].
  • To evaluate the optimum treatment strategy for metastatic adrenal tumors derived from non-small cell lung cancer (NSCLC), we retrospectively analyzed 17 consecutive cases (8 resection cases: 4 synchronous and 4 metachronous: 9 non-resection cases: 3 synchronous and 6 metachronous) who received surgical resection for NSCLC.
  • Of these, 9, 3, 2, 2, and 1 patient (s) were diagnosed as having adenocarcinoma, squamous cell carcinoma, pleomorphic carcinoma, large cell carcinoma, and adenosquamous cell carcinoma, respectively.
  • The mean interval after lung resection and treatment of metachronous adrenal metastasis was 9.9 months.
  • The mean time to progression from treatment of metachronous adrenal metastasis to disease progression was 8.9 months.
  • The 2-year survival of patients following resection versus those who did not undergo a resection for adrenal metastasis was 62.5 and 22.8%, respectively.
  • These data indicate that metastatic adrenal tumors should be resected if the patient can tolerate surgery after appropriate selection.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / therapy. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology


21. Lane BR, Tiong HY, Campbell SC, Fergany AF, Weight CJ, Larson BT, Novick AC, Flechner SM: Management of the adrenal gland during partial nephrectomy. J Urol; 2009 Jun;181(6):2430-6; discussion 2436-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of the adrenal gland during partial nephrectomy.
  • The indications for adrenalectomy in patients undergoing partial nephrectomy are not clearly defined and some surgeons perform it routinely for large and/or upper pole renal tumors.
  • We analyzed initial management and oncological outcomes of adrenal glands after open partial nephrectomy.
  • During partial nephrectomy the ipsilateral adrenal gland was resected if a suspicious adrenal nodule was noted on radiographic imaging, or if intraoperative findings indicated direct extension or metastasis.
  • Pathological analysis revealed direct invasion of the adrenal gland by renal cell carcinoma (1), renal cell carcinoma metastasis (2), other adrenal neoplasms (3) or benign tissue (42, 87%).
  • Metachronous adrenalectomy was ipsilateral (10), contralateral (2) or bilateral (3), revealing metastatic renal cell carcinoma in 11 patients.
  • We propose concomitant adrenalectomy only if a suspicious adrenal lesion is identified radiographically or invasion of the adrenal gland is suspected intraoperatively.
  • Even using such strict criteria only 13% of these suspicious adrenal nodules contained cancer.
  • The rarity of metachronous adrenal metastasis and the lack of an observable benefit to concomitant adrenalectomy support adrenal preservation during partial nephrectomy except as previously outlined.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Nephrectomy / methods
  • [MeSH-minor] Adrenal Glands. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19371896.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Lu Y, Xie D, Huang W, Gong H, Yu J: 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients. Neoplasma; 2010;57(2):129-34
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients.
  • The aim of this study was to assess the usefulness of integrated (18)F-FDG PET/CT in differentiating benign from metastatic malignant adrenal masses in patients with lung cancer.
  • One hundred and ten adrenal masses (size range, 0.5 - 6.3 cm, mean size, 1.9 cm) were evaluated retrospectively in 87 lung cancer patients.
  • PET findings were interpreted as positive if the (18)F-FDG uptake of the adrenal mass was greater than or equal to that of the liver.
  • PET findings were interpreted as negative if the 18F-FDG uptake of the adrenal mass was less than that of the liver.
  • PET/CT findings were positive in 77 adrenal masses.
  • Seventy-four of these were eventually considered to be metastatic adrenal disease.
  • In the end, histopathological examinations of the adrenal lesions demonstrated the presence of adenomas.
  • PET/CT findings were negative in 33 adrenal masses, of which 31 eventually proved to be benign.
  • The 2 adrenal masses that were false-negative, underwent PET/CT twice with a two-month interval.
  • Both adrenal masses were interpreted as metastasis.
  • Integrated (18)F-FDG PET-CT is an accurate, noninvasive technique for differentiating benign from metastatic adrenal lesions detected on CT or MRI in patients with lung cancer.
  • It allows early detection and accurate localization of adrenal lesions and differentiation of metastatic nodules from benign lesions, thereby facilitating treatment planning.
  • [MeSH-major] Adrenal Gland Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed
  • [MeSH-minor] Adenocarcinoma / radiography. Adenocarcinoma / radionuclide imaging. Adenocarcinoma / secondary. Adult. Aged. Carcinoma, Large Cell / radiography. Carcinoma, Large Cell / radionuclide imaging. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / secondary. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Small Cell Lung Carcinoma / radiography. Small Cell Lung Carcinoma / radionuclide imaging. Small Cell Lung Carcinoma / secondary


23. Quayle FJ, Spitler JA, Pierce RA, Lairmore TC, Moley JF, Brunt LM: Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous. Surgery; 2007 Oct;142(4):497-502; discussion 502-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous.
  • INTRODUCTION: The role of fine needle aspiration (FNA) biopsy in patients with incidentally discovered adrenal masses is limited.
  • The purpose of this study was to review the value of FNA biopsy of adrenal masses in patients referred to a large university endocrine surgical practice.
  • METHODS: Patients referred to the endocrine surgery service at our institutions from 1997 through 2006 for evaluation of an adrenal mass were identified and those who underwent needle biopsy were selected for analysis.
  • RESULTS: Of the 347 patients evaluated for adrenal masses, 22 (6.3%) had undergone needle biopsy before referral.
  • Clinical presentations were incidentaloma (n = 15), suspected metastasis (n = 4), and symptomatic large mass (n = 3).
  • Biopsies were diagnostic in 2 of 4 patients with suspected metastasis and in 1 of 3 patients with a large symptomatic mass.
  • CONCLUSIONS: FNA biopsy is not useful in the diagnostic workup of patients with incidentally discovered adrenal masses and rarely alters management in patients with resectable adrenal metastases and primary adrenal malignancies.
  • Language that suggests biopsy of adrenal masses should be avoided in radiology reports.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Biopsy, Needle / adverse effects. Biopsy, Needle / contraindications. Pheochromocytoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Renal Cell / secondary. Female. Hematoma / etiology. Hemothorax / etiology. Humans. Kidney Neoplasms / pathology. Male. Melanoma / secondary. Middle Aged. Paraganglioma / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950341.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Owecki M, Baszko-Błaszyk D, Waśko R, Sowiński J: [Non-small cell lung cancer presenting under the mask of a primary adrenal cancer--case report]. Pol Merkur Lekarski; 2005 Feb;18(104):216-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-small cell lung cancer presenting under the mask of a primary adrenal cancer--case report].
  • Adrenal carcinoma is a malignant disease that often results in distant metastases to different organs, including the lungs.
  • While diagnosing patients with suspected adrenal carcinoma, metastases to the lungs should always be considered.
  • The opposite clinical situation also should be considered, i.e. lung cancer metastases to the adrenal gland.
  • Both conditions may have a very similar course and their differential diagnosis may be sometimes very difficult.
  • However, proper diagnosis is of great importance because both diseases are treated by different means.
  • We present a case of a 50-year-old female patient with a small primary focus of non-small cell lung carcinoma and its large metastasis to the left adrenal gland, accompanied by SIADH and paraneoplastic hypercalcemia.
  • In the presented case adrenal carcinoma and its lung metastasis were primarily misdiagnosed which led to unnecessary laparotomy.
  • The proper diagnosis was enabled by CT guided biopsy of the lung tumor.
  • [MeSH-major] Adrenal Gland Neoplasms / radiography. Adrenal Gland Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / radiography. Carcinoma, Non-Small-Cell Lung / secondary. Diagnostic Errors. Lung Neoplasms / radiography
  • [MeSH-minor] Adrenalectomy. Biopsy, Needle / methods. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Laparoscopy. Middle Aged. Palliative Care. Tomography, X-Ray Computed. Unnecessary Procedures


25. Fujiwara M, Kamma H, Wu W, Yano Y, Homma S, Satoh H: Alternative lengthening of telomeres in the human adrenocortical carcinoma cell line H295R. Int J Oncol; 2006 Aug;29(2):445-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternative lengthening of telomeres in the human adrenocortical carcinoma cell line H295R.
  • It has been reported that clinical samples of adrenocortical carcinoma show a low incidence of telomerase positivity.
  • We characterized an adrenocortical carcinoma cell line, H295R, focusing on the telomere maintenance mechanism, and compared it with telomerase-positive 293 cells and HeLa cells.
  • H295R cells had long and heterogeneous telomere DNA, and FISH revealed large nuclear bodies in a few interphase nuclei, which presumably represented ALT-associated PML bodies.
  • In conclusion, the H295R adrenocortical carcinoma cell line is negative for telomerase and maintains its telomeres by the ALT mechanism.
  • [MeSH-major] Adrenal Cortex Neoplasms / ultrastructure. Carcinoma / ultrastructure. Telomere / ultrastructure
  • [MeSH-minor] Cell Line, Tumor. Cell Nucleus / metabolism. HeLa Cells. Humans. In Situ Hybridization, Fluorescence. Neoplasms / metabolism. Oligonucleotides / chemistry. Phenotype. Reverse Transcriptase Polymerase Chain Reaction. Telomerase / metabolism

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820888.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Oligonucleotides; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


26. Prando A, Prando D, Prando P: Renal cell carcinoma: unusual imaging manifestations. Radiographics; 2006 Jan-Feb;26(1):233-44
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma: unusual imaging manifestations.
  • Unusual radiologic manifestations of a renal cell carcinoma (RCC) can present a diagnostic challenge.
  • These manifestations include bilateral synchronous multifocal tumors, a small RCC with synchronous adrenal metastasis, and RCC associated with bulky abdominal lymphoma.
  • Less common manifestations include multiseptated cystic carcinoma simulating a moderately complex renal cyst at ultrasonography (US), paraaortic metastatic adenopathy as the only sign of an undetectable primary renal neoplasm, RCC causing a large arteriovenous fistula, RCC simulating angiomyolipoma, and a nonfunctioning kidney due to transparenchymal renal propagation of cancer associated with a tumor thrombus occluding the renal vein.
  • Radiologists should be aware of the possibility of tumor multifocality or of adrenal metastases from a high-grade small renal tumor, as well as of the association of RCC with lymphoma.
  • They should also be aware of the importance of following up a multiseptated cystic mass found at US or a Bosniak category IIF renal cyst, since these lesions can serve as early indicators of cystic carcinoma.
  • Because the clinical implications of and therapeutic strategies for RCC vary depending on imaging characterization of the nature and extent of the disease, familiarity with its more unusual radiologic manifestations facilitates accurate diagnosis and management.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2006.
  • (PMID = 16418254.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Sugaya M, Takenoyama M, Shigematsu Y, Baba T, Fukuyama T, Nagata Y, Mizukami M, So T, Ichiki Y, Yasuda M, So T, Hanagiri T, Sugio K, Yasumoto K: Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung. Int J Cancer; 2007 Mar 1;120(5):1055-62
Cellosaurus - a cell line knowledge resource. culture/stock collections - A904L (CVCL_U095) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung.
  • The aim of the present study was to elucidate the tumor-specific cellular immunological responses occurring in a patient with large cell carcinoma of the lung who had no evidence of recurrence following surgical resections of both a primary lung lesion and a metastatic adrenal lesion.
  • The F2b possessed T cell receptor (TCR) using the Valpha5 and Vbeta7 gene segment.
  • The F2b recognized 3 out of 7 HLA-A24 positive allogeneic tumor cell lines and in 1 out of 7 HLA-A24 negative allogeneic tumor cell lines when transfected with HLA-A24.
  • [MeSH-major] Antigens, Neoplasm / isolation & purification. Carcinoma, Large Cell / immunology. HLA-A Antigens / analysis. Lung Neoplasms / immunology. Microfilament Proteins / genetics. Oligopeptides / isolation & purification. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Alternative Splicing. Amino Acid Sequence. Cytotoxicity, Immunologic / genetics. DNA, Complementary / genetics. Gene Expression. HLA-A24 Antigen. Humans. Molecular Sequence Data. Neoplasm Recurrence, Local / diagnosis. Peptides / genetics. Peptides / immunology. Peptides / isolation & purification. Receptors, Antigen, T-Cell / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 17131342.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA, Complementary; 0 / HLA-A Antigens; 0 / HLA-A*24:02 antigen; 0 / HLA-A24 Antigen; 0 / Microfilament Proteins; 0 / NYGFQIHTK; 0 / Oligopeptides; 0 / Peptides; 0 / Receptors, Antigen, T-Cell; 0 / TRIOBP protein, human
  •  go-up   go-down


28. Zigeuner R, Pummer K: [Current surgical aspects of renal cell carcinoma]. Wien Med Wochenschr; 2009;159(21-22):535-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current surgical aspects of renal cell carcinoma].
  • Surgery of renal cell carcinoma (RCC) has undergone substantial changes during the past years.
  • Currently, laparoscopic nephrectomy is considered a golden standard for renal masses larger than 4 cm (T1b-T2), whereas open radical nephrectomy is reserved for large, locally advanced tumours, caval extension or enlarged lymph nodes.
  • Adrenalectomy can be omitted if the adrenal appears normal.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Laparoscopy / methods. Nephrectomy / methods

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19997839.001).
  • [ISSN] 1563-258X
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 53
  •  go-up   go-down


29. Ohno Y, Izumi M, Tachibana M, Kawamura T, Yoshioka K, Aoyagi T, Ohori M, Namiki K, Sakamoto N, Nakagami Y, Hatano T, Akimoto S, Nishimura T: Characterization and gene expression analysis of novel matched primary and metastatic renal cell carcinoma cell lines. Oncol Rep; 2008 Sep;20(3):501-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization and gene expression analysis of novel matched primary and metastatic renal cell carcinoma cell lines.
  • Despite recent advances in molecular biology that have clarified the mechanisms involved in the metastasis of several types of cancer, the molecular mechanism underlying the metastasis of renal cell carcinoma (RCC) remains unclear.
  • Two RCC cell lines were successfully established from the surgical specimens of a matched primary tumor and adrenal metastasis from the same RCC patient, and were designated as TMK-1P and TMK-1M, respectively.
  • DNA microarray analysis showed a large differential expression of genes related to cell adhesion and the extracellular matrix molecules of which hexabrachion (tenascin-C), epidermal growth factor receptor, cadherin-6, and beta1-catenin were down-regulated, and the 67 kDa laminin receptor 1 and transforming growth factor-beta-induced 68 kDa protein (betaig-h3) were up-regulated in TMK-1M.
  • Real-time RT-PCR analysis confirmed this differential gene expression between the two cell lines.
  • The RCC cell lines may be useful in studying tumor invasion and screening markers for metastasis.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Biomarkers, Tumor / genetics. Carcinoma, Renal Cell / genetics. Gene Expression Regulation, Neoplastic. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology
  • [MeSH-minor] Cell Line, Tumor. Gene Expression Profiling. Humans. Karyotyping. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695898.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


30. Sharma R, Ganpule A, Veeramani M, Sabnis RB, Desai M: Laparoscopic management of adrenal lesions larger than 5 cm in diameter. Urol J; 2009;6(4):254-9
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic management of adrenal lesions larger than 5 cm in diameter.
  • INTRODUCTION: Laparoscopic adrenalectomy remains a controversial procedure for large tumors.
  • The incidence of adrenocortical carcinoma increases and technical difficulty of adrenalectomy increases as the size increases.
  • They were compared with patients whose adrenal tumors were smaller than 5 cm.
  • RESULTS: Patients with small tumors (< 5 cm) had a significantly shorter median operative time of 90 minutes as compared to 145 minutes in those with large tumors (> 5 cm).
  • There was no significant difference in the median hemoglobin drop (1.05 g/dL versus 1.30 g/dL), time for starting oral intake (24 hours in both groups) or hospital stay (3.5 days versus 4.0 days) between patients with small and large tumors, respectively.
  • There were no intra-operative complications except for 1 incidence of supraventricular tachycardia in a patient with a large pheochromocytoma.
  • Histopathology of large tumors revealed 16 benign tumors (8 pheochromocytomas, 4 adenomas, 2 ganglioneuromas, 1 pseudocyst, and 1 myelolipoma) and 3 malignancies, of which 1 was primary adrenocortical carcinoma and 2 were metastatic renal cell carcinoma.
  • CONCLUSION: In experienced hands, laparoscopic adrenalectomy is safe and feasible for large functioning adrenal tumors.
  • Large adrenal tumors suspicious of harboring malignancy with no peri-adrenal involvement can be tackled laparoscopically.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Laparoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20027553.001).
  • [ISSN] 1735-546X
  • [Journal-full-title] Urology journal
  • [ISO-abbreviation] Urol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


31. Terrone C, Gontero P, Volpe A, Porpiglia F, Bollito E, Zattoni F, Frea B, Tizzani A, Fontana D, Scarpa RM, Rossetti SR: Proposal of an improved prognostic classification for pT3 renal cell carcinoma. J Urol; 2008 Jul;180(1):72-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proposal of an improved prognostic classification for pT3 renal cell carcinoma.
  • PURPOSE: The prognostic accuracy of the current TNM 2002 staging system for locally advanced renal cell carcinoma has been questioned.
  • To contribute to the development of a more accurate classification for this stage of disease we assessed the correlation between patterns of invasion in the pT3 category and outcomes in a large multi-institutional series.
  • MATERIALS AND METHODS: Pathological data and clinical followup on 513 pT3 renal cell carcinoma cases treated with radical nephrectomy between 1983 and 2005 at 3 Italian academic centers were retrospectively reviewed.
  • Simultaneous perirenal fat and sinus fat invasion or perirenal fat and vascular invasion as well as adrenal gland involvement characterized high risk tumors.
  • CONCLUSIONS: We confirm that the prognostic usefulness of the current 2002 TNM system for pT3 renal cell carcinoma is limited.
  • Large prospective series are needed to validate these findings.
  • [MeSH-major] Carcinoma, Renal Cell / classification. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / classification. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18485380.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


32. Tauchmanovà L, Pensabene M, Capuano I, Spagnoletti I, Zeppa P, Del Vecchio S, Mainenti M, De Rosa G, Colao A, Contegiacomo A: Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: response to chemotherapy and octreotide LAR. J Endocrinol Invest; 2005 Apr;28(4):371-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: response to chemotherapy and octreotide LAR.
  • We here describe the case of a 72-yr-old woman with evidence of a poorly differentiated small-cell neuroendocrine carcinoma (NEC) localized in different endocrine glands and other non-endocrine organs.
  • In particular, a large ovarian mass, multinodular thyroid goiter, right adrenal mass, cystic liver metastases and anterior mediastinum lymph node metastasis were present.
  • Diagnosis of poorly differentiated metastasized NEC of unknown origin was made on the basis of histological and immunohistochemical findings, and treatment with etoposide (100 mg/m2 in days 1, 2 and 3) and cisplatinum (45 mg/m2 in days 2 and 3) was initiated.
  • Rapid improvement of dyspnea and a reduction of the largest thyroid nodule, liver metastases and adrenal mass by 50% were observed after 3 months of treatment; the dimensions remained stable thereafter, while the pericardial lymph node disappeared.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Liver Neoplasms / secondary. Neoplasms, Unknown Primary / drug therapy. Neuroendocrine Tumors / drug therapy. Octreotide / therapeutic use. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966513.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  •  go-up   go-down


33. Hirose A, Okada Y, Fukushima A, Tanaka Y: [A rare case of primary aldosteronism caused by bilateral functioning adrenocortical adenomas with renal cell carcinoma]. J UOEH; 2005 Dec 1;27(4):315-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A rare case of primary aldosteronism caused by bilateral functioning adrenocortical adenomas with renal cell carcinoma].
  • We report a rare case of bilateral primary aldosteronism with renal cell carcinoma.
  • Abdominal CT and MRI revealed tumor masses in both adrenal glands, and a large left renal mass.
  • The preoperative diagnosis was primary aldosteronism due to bilateral functioning adrenocortical adenomas and left renal cell carcinoma.
  • The Pathological diagnosis was left renal cell carcinoma and bilateral functioning adrenocortical adenomas.
  • Primary aldosteronism due to bilateral functioning adrenocortical adenomas is relatively rare and its complication with renal cell carcinoma is an extremely rare case.
  • [MeSH-major] Adrenal Cortex Neoplasms / complications. Adrenocortical Adenoma / complications. Carcinoma, Renal Cell / complications. Hyperaldosteronism / etiology. Kidney Neoplasms / complications


34. Garg K, Lee P, Ro JY, Qu Z, Troncoso P, Ayala AG: Adenomatoid tumor of the adrenal gland: a clinicopathologic study of 3 cases. Ann Diagn Pathol; 2005 Feb;9(1):11-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of the adrenal gland: a clinicopathologic study of 3 cases.
  • Rare extragenital adenomatoid tumors have been identified in the adrenal glands, heart, mesentery, pleura, and lymph nodes.
  • In the adrenal gland, adenomatoid tumors may pose a diagnostic challenge.
  • The differential diagnosis includes adrenocortical carcinoma and metastatic carcinoma, especially signet ring cell carcinoma.
  • We present 3 cases of adrenal adenomatoid tumors, including one with a concurrent large hemorrhagic vascular adrenal cyst.
  • One patient presented with abdominal pain due to the presence of a concurrent large adrenal cyst.
  • In our experience, the key to the diagnosis of this rare benign tumor is to consider adenomatoid tumor in the differential diagnosis of any glandular tumor occurring in the adrenal gland.
  • [MeSH-major] Adenoma / pathology. Adrenal Gland Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Biomarkers, Tumor / metabolism. Calbindin 2. Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / secondary. Cysts / complications. Cysts / metabolism. Cysts / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / metabolism. Male. Middle Aged. S100 Calcium Binding Protein G / metabolism. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692945.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 68238-35-7 / Keratins
  •  go-up   go-down


35. Wagner B, Patard JJ, Méjean A, Bensalah K, Verhoest G, Zigeuner R, Ficarra V, Tostain J, Mulders P, Chautard D, Descotes JL, de la Taille A, Salomon L, Prayer-Galetti T, Cindolo L, Valéri A, Meyer N, Jacqmin D, Lang H: Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol; 2009 Feb;55(2):452-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma.
  • BACKGROUND: The prognostic significance of venous tumor thrombus extension in patients with renal cell carcinoma (RCC) is a matter of many controversies in the current literature.
  • OBJECTIVE: To evaluate the prognostic role of inferior vena cava (IVC) involvement in a large series of pT3b and pT3c RCCs.
  • Age, gender, clinical symptoms, Eastern Cooperative Oncology Group (ECOG) performance status, TNM stage, tumor size, adrenal invasion, perinephric fat invasion, histological type, and Fuhrman grade were reviewed.
  • CONCLUSIONS: The level of tumor thrombus in the IVC does not significantly affect long-term overall survival in patients with renal cell carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Nephrectomy / methods. Renal Veins / pathology. Vena Cava, Inferior / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2009 Feb;55(2):459 [18692952.001]
  • [CommentIn] Eur Urol. 2009 Feb;55(2):460 [18692949.001]
  • (PMID = 18692951.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


36. Shah SR, Purcell GP, Malek MM, Kane TD: Laparoscopic right adrenalectomy for a large ganglioneuroma in a 12-year-old. J Laparoendosc Adv Surg Tech A; 2010 Feb;20(1):95-6
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic right adrenalectomy for a large ganglioneuroma in a 12-year-old.
  • INTRODUCTION: Laparoscopic adrenalectomy is well established as the standard technique for all indications of adrenalectomy except adrenal carcinoma; however, some also consider large adrenal masses a relative contraindication.
  • We present a video of a laparoscopic excision of a large ganglioneuroma and right adrenalectomy in a 12-year-old female.
  • Upon surgical consultation, she underwent a magnetic resonance imaging, which showed a 7.9 x 4.4 x 5.6 cm heterogeneously enhancing suprarenal lesion that was either arising from or compressing the right adrenal gland.
  • A flexible 5-mm liver retractor (Mediflex; Velmed, Inc., Wexford, PA) was placed directly through the abdominal wall without a trocar in order to elevate the liver from the area of the right adrenal and retroperitoneum.
  • The pathology revealed an 8.5 x 7.0 x 3.0 cm ganglioneuroma, with primarily neural and Schwann cell-type tissue with interspersed large, prominent ganglion cells, and a normal adrenal gland.
  • CONCLUSIONS: As demonstrated by our video, large adrenal masses in the pediatric population can be successfully excised laparoscopically with appropriate surgeon comfort and experience.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Ganglioneuroma / surgery. Laparoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19489680.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [General-notes] NLM/ Original DateCompleted: 20100519
  •  go-up   go-down


37. Bakshi N, Kunju LP, Giordano T, Shah RB: Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors: diagnostic Implications. Appl Immunohistochem Mol Morphol; 2007 Sep;15(3):310-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors: diagnostic Implications.
  • Antibody to renal cell carcinoma (RCC) antigen, a normal human proximal brush border antigen, has recently become commercially available and reported to be highly specific and a relatively sensitive marker for RCC.
  • Of the nonrenal tumors occasional carcinomas have been reported to express RCC, notably breast carcinoma.
  • Using tissue microarrays, we investigated the use of RCC on a large number of renal epithelial neoplasms (RENs) and nonrenal tumors, especially those potentially confused with REN.
  • Three tissue microarrays containing 241 REN samples, 192 samples of a wide variety of neoplasms and 170 adrenal tumor samples, respectively, were stained with RCC monoclonal antibody.
  • Out of 241 REN, 173 were positive for RCC (sensitivity 72%): clear cell 72%, papillary 95%, chromophobe 91%, unclassified 85%, oncocytoma 75%, sarcomatoid 20%, and metastatic RCC 40%.
  • The overall immunostaining intensity was consistently much higher in papillary and clear cell RCC than in other tumors.
  • RCC expression was seen equally among adrenal adenoma and carcinoma group.
  • Eight out of 28 (28.5%) normal adrenal cores also stained for RCC.
  • RCC is a relatively useful marker in the differential diagnosis of REN only if used in a panel with other positive and negative markers.
  • RCC does not reliably differentiate REN, especially classic clear cell type, from adrenocortical neoplasms, which are frequently confused due to close anatomic proximity and similar morphology.
  • [MeSH-major] Antigens, Neoplasm / analysis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Mitogen-Activated Protein Kinases / analysis
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Tissue Array Analysis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721277.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; EC 2.7.11.22 / MOK protein, human; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


38. Novara G, Ficarra V, Antonelli A, Artibani W, Bertini R, Carini M, Cosciani Cunico S, Imbimbo C, Longo N, Martignoni G, Martorana G, Minervini A, Mirone V, Montorsi F, Schiavina R, Simeone C, Serni S, Simonato A, Siracusano S, Volpe A, Carmignani G, SATURN Project-LUNA Foundation: Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol; 2010 Oct;58(4):588-95
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed?
  • Specifically, T2 cancers were subclassified into T2a and T2b (< or =10 cm vs >10 cm), tumors with renal vein involvement or perinephric fat involvement were classified as T3a cancers, and those with adrenal involvement were classified as T4 cancers.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Neoplasm Staging / standards

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • [CommentIn] J Urol. 2011 Apr;185(4):1223 [22115474.001]
  • [CommentIn] Eur Urol. 2010 Oct;58(4):517-9; discussion 519-21 [20728266.001]
  • [ErratumIn] Eur Urol. 2011 Jan;59(1):182. Schiavina, Roberto [corrected to Schiavina, Riccardo]
  • (PMID = 20674150.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Validation Studies
  • [Publication-country] Switzerland
  • [Investigator] De Cobelli O; Schiavina R; Antonelli A; Corti S; Cosciani Cunico S; Simeone C; Castelli M; Cimino S; Favilla V; Morgia G; Billia M; Terrone C; Volpe A; Imbimbo C; Longo N; Mirone V; Carini M; Masieri L; Minervini A; Serni S; Carmignani G; Oneto F; Simonato A; Varca V; Rocco F; Artibani W; Ficarra V; Novara G; Costantini E; Porena M; Zucchi A; Morgia G; Ciciliato S; Lampropoulou N; Siracusano S; Fontana D; Gontero P; Tizzani A; Brunelli M; Martignoni G; Valotto C; Zattoni F
  •  go-up   go-down


39. Bodtger U, Vilmann P, Clementsen P, Galvis E, Bach K, Skov BG: Clinical impact of endoscopic ultrasound-fine needle aspiration of left adrenal masses in established or suspected lung cancer. J Thorac Oncol; 2009 Dec;4(12):1485-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact of endoscopic ultrasound-fine needle aspiration of left adrenal masses in established or suspected lung cancer.
  • A left adrenal gland (LAG) mass is found in 5 to 16%, and malignancy preclude surgery.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Biopsy, Fine-Needle / methods. Endoscopy. Lung Neoplasms / pathology. Lung Neoplasms / ultrasonography. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenocarcinoma / ultrasonography. Adult. Aged. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / surgery. Carcinoma, Large Cell / ultrasonography. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Non-Small-Cell Lung / ultrasonography. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / ultrasonography. Endosonography. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Prognosis. Retrospective Studies. Small Cell Lung Carcinoma / pathology. Small Cell Lung Carcinoma / surgery. Small Cell Lung Carcinoma / ultrasonography. Treatment Outcome


40. Dahl E, Wiesmann F, Woenckhaus M, Stoehr R, Wild PJ, Veeck J, Knüchel R, Klopocki E, Sauter G, Simon R, Wieland WF, Walter B, Denzinger S, Hartmann A, Hammerschmied CG: Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene; 2007 Aug 16;26(38):5680-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
  • To evaluate the incidence of SFRP1 deficiency in human tumours, we performed a large-scale SFRP1 expression analysis using immunohistochemistry on a comprehensive tissue microarray (TMA) comprising 3448 tumours from 36 organs.
  • Although tumour precursor stages of, for example kidney, colon, endometrium or adrenal gland still exhibited moderate to abundant SFRP1 expression, this expression was frequently lost in the corresponding genuine tumours.
  • We defined nine novel tumour entities with apparent loss of SFRP1 expression, i.e., cancers of the kidney, stomach, small intestine, pancreas, parathyroid, adrenal gland, gall bladder, endometrium and testis.
  • Renal cell carcinoma (RCC) exhibited the highest frequency of SFRP1 loss (89% on mRNA level; 75% on protein level) and was selected for further analysis to investigate the cause of SFRP1 loss in human tumours.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. DNA Methylation. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kidney Neoplasms / genetics. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology. Loss of Heterozygosity. Middle Aged. Promoter Regions, Genetic / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353908.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / SFRP1 protein, human
  •  go-up   go-down


41. Cassoni P, Daniele L, Maldi E, Righi L, Tavaglione V, Novello S, Volante M, Scagliotti GV, Papotti M: Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases. Histopathology; 2009 Jul;55(1):20-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases.
  • None of the pure bronchioloalveolar carcinomas proved to be positive, vs. 42.8% of the large cell carcinomas (neuroendocrine subtype excluded).
  • Adenocarcinomas (8.5%), large cell neuroendocrine carcinomas (20%) and squamous cell carcinomas (29.6%) displayed an intermediate percentage of positive cases, suggesting a gradient of Cav-1 expression according to tumour histotype-related aggressiveness.
  • This pattern was exclusive to the brain, as it was not acquired in adrenal metastases.
  • CONCLUSIONS: Cav-1 immunoreactivity in lung carcinoma is histotype-dependent and acquired de novo in brain metastases, suggesting a site-specific phenotypic shift in secondary lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Carcinoma, Large Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Caveolin 1 / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adrenal Gland Neoplasms / metabolism. Adrenal Gland Neoplasms / secondary. DNA, Neoplasm / genetics. Disease Progression. Gene Amplification / genetics. Gene Expression Regulation, Neoplastic. Humans. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19614763.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Caveolin 1; 0 / DNA, Neoplasm; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


42. Ficarra V, Galfano A, Guillé F, Schips L, Tostain J, Mejean A, Lang H, Mulders P, De La Taille A, Chautard D, Descotes JL, Cindolo L, Novara G, Rioux-Leclercq N, Zattoni F, Artibani W, Patard JJ: A new staging system for locally advanced (pT3-4) renal cell carcinoma: a multicenter European study including 2,000 patients. J Urol; 2007 Aug;178(2):418-24; discussion 423-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new staging system for locally advanced (pT3-4) renal cell carcinoma: a multicenter European study including 2,000 patients.
  • PURPOSE: We provide an adequate prognostic stratification for locally advanced renal cell carcinoma and propose a new TNM classification.
  • MATERIALS AND METHODS: We analyzed clinical and pathological data on a large series of patients undergoing radical nephrectomy for pT3-4 renal cell carcinoma at 12 European centers.
  • According to median survival we identified 3 prognostic groups, including 1--patients with renal vein thrombosis (117 months), fat invasion (98 months) or infradiaphragmatic vena caval thrombosis (67 months), 2--patients with adrenal invasion alone (24 months), renal vein thrombosis plus fat invasion (24 months) or infradiaphragmatic vena cava plus fat invasion (24 months) and 3--patients with renal or infradiaphragmatic caval thrombosis plus adrenal involvement (11 months), supradiaphragmatic vena caval thrombosis (12 months) or Gerota's fascia invasion (12 months).
  • CONCLUSIONS: Our results suggest the necessity of reclassifying locally advanced renal cell carcinoma according to the 3 described prognostic categories.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Neoplasm Staging / methods
  • [MeSH-minor] Adrenal Glands / pathology. Aged. Europe. Female. Humans. Kaplan-Meier Estimate. Kidney / pathology. Lymphatic Metastasis / pathology. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplastic Cells, Circulating. Nephrectomy. Prognosis. Renal Veins / pathology. Vena Cava, Inferior / pathology


43. Mansouri D, Dimet S, Couanet D, Terrier-Lacombe MJ, Vasiliu V, Khalifa C, Suciu V, Vielh P: Renal cell carcinoma with an Xp11.2 translocation in a 16-year-old girl: a case report with cytological features. Diagn Cytopathol; 2006 Nov;34(11):757-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma with an Xp11.2 translocation in a 16-year-old girl: a case report with cytological features.
  • Ultrasound and abdominal pelvic CAT scan revealed a large heterogeneous mass with calcifications in the inferior portion of the left kidney.
  • Cytological analysis revealed highly cellular smears with malignant cells arranged in large clusters or rarely isolated, sometimes surrounding hyaline nodules with numerous psammoma bodies.
  • The diagnosis of a special type of renal cell carcinoma was suspected, and was then confirmed after examination of the biopsy sample and the corresponding surgical specimen.
  • The histomorphologic features were those of a renal cell carcinoma associated with an Xp11.2 translocation.
  • The clinical outcome was marked several months later by metastases in lymph nodes, bone, lung, and adrenal gland as well as a local recurrence.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / pathology. Chromosomes, Human, X / genetics. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology. Translocation, Genetic

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (C) 2006 Wiley-Liss, Inc.
  • (PMID = 17121199.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Moch H, Artibani W, Delahunt B, Ficarra V, Knuechel R, Montorsi F, Patard JJ, Stief CG, Sulser T, Wild PJ: Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol; 2009 Oct;56(4):636-43
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma.
  • CONTEXT: The outcome prediction for renal cell cancer (RCC) remains controversial, and although many parameters have been tested for prognostic significance, only a few have achieved widespread acceptance in clinical practice.
  • EVIDENCE ACQUISITION: A literature search in English was performed using the National Library of Medicine database and the following keywords: renal cell cancer, kidney neoplasm, and staging.
  • EVIDENCE SYNTHESIS: The prognostic significance of tumour size for localized RCC has been investigated in a large number of studies.
  • In detail, perirenal fat invasion, direct infiltration of the ipsilateral adrenal gland, invasion of the urinary collecting system, infiltration of renal sinus fat, and vena cava and renal vein thrombosis are disputed.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19595500.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 62
  •  go-up   go-down


45. Weng CT, Chu PY, Liu MT, Chen MK: Small cell carcinoma of the head and neck: a single institution's experience and review of the literature. J Otolaryngol Head Neck Surg; 2008 Dec;37(6):788-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the head and neck: a single institution's experience and review of the literature.
  • OBJECTIVES: It is well known that small cell carcinoma (SmCC) arising at extrapulmonary sites leads to a poor prognosis for patients.
  • Owing to the infrequency of primary SmCC of the head and neck, it is very unlikely that any large, controlled study will ever be performed.
  • Their outcomes are as follows: two patients died, one has adrenal and bone metastasis but is still alive, and one shows no evidence of disease after treatment.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19128705.001).
  • [ISSN] 1916-0216
  • [Journal-full-title] Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
  • [ISO-abbreviation] J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 2
  •  go-up   go-down


46. Antonelli A, Zani D, Cozzoli A, Cunico SC: Surgical treatment of metastases from renal cell carcinoma. Arch Ital Urol Androl; 2005 Jun;77(2):125-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of metastases from renal cell carcinoma.
  • INTRODUCTION: Even if the number of curable renal cancers increased during the last decades, there is still a considerable amount of patients with distant metastases, evidenced at diagnosis or during the follow-up, without real curative therapeutic options.
  • The metastatic disease was evidenced at the diagnosis of renal tumour in 118 patients (9.9%), during the follow up at a mean distance of 18.6 months in 134 (11.3%) and was in a single organ in 200 patients, in multiple sites in 52.
  • RESULTS: The patients with a single-site metastasis who underwent of metastases removal, especially when pulmonary or adrenal, showed a better prognosis than the ones otherwise treated, while in the patients with bony metastases, multiple-site metastases and the ones who did not receive any curative therapies an extremely dismal prognosis was evidenced.
  • However, a large amount of the patients with a single-site metastasis (79% on 159 treated patients) had a relapse of the disease, even when surgically treated (69%).
  • Thus, even if the initial bias in the selection of patients is surely significant, in our opinion, each patient with good performance status and a resectable metastatic lesion, better if pulmonary or adrenal, should undergo surgical treatment of metastases, that could provide long-term survival in a small part of the patients.

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146280.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


47. Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ: Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Am J Surg Pathol; 2009 Aug;33(8):1125-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
  • In addition to lowering this risk, RRSO also offers the opportunity to detect occult early-stage fallopian tube or ovarian carcinoma.
  • The differential diagnosis of occult tubal/ovarian cancer includes a spectrum of benign tubal and ovarian alterations and also occult metastatic breast cancer, although only rare cases of the latter have been reported in RRSO.
  • With the aim of elucidating features which may help with differential diagnosis, this study reports the incidence and pathologic features of benign ovarian alterations, benign ovarian tumors, and occult primary and metastatic malignancies in prophylactic oophorectomies from 108 women with a BRCA mutation and from 35 women with other strong risk factors for hereditary breast/ovarian carcinoma.
  • Occult primary carcinoma occurred in 7 (6.5%) BRCA patients (5 in fallopian tube, 1 in fallopian tube and ovary, 1 in ovary).
  • In contrast, ovarian metastases in the non-RRSO population were all clinically detected, bilateral, large, and exhibited well-developed malignant cytologic features.
  • None of the normal cell types in the ovary or tube demonstrated any cytologic alterations in RRSO patients who received neoadjuvant chemotherapy.
  • The main morphologic mimics of metastasis with superimposed chemotherapy-induced alterations in RRSO were stromal hyperthecosis (n=8), nodular hyperthecosis (n=2), adrenal rests (n=3), hilus cell nodules (n=43), and hilus cell hyperplasia (n=4).
  • Occult primary ovarian carcinoma was reliably distinguished from ovarian metastases of breast cancer by WT-1+, p53+, mammaglobin-, GCDPF-immunoprofile.
  • These results demonstrate that evaluation of RRSO specimens requires awareness of a spectrum of ovarian lesions which may mimic occult primary or metastatic carcinoma; awareness of the masquerading effects of neoadjuvant chemotherapy; and awareness of the potential morphologic differences between occult metastatic breast cancer in RRSO and non-RRSO specimens.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Diagnosis, Differential. Fallopian Tubes / surgery. Female. Genetic Predisposition to Disease. Humans. Mutation. Neoplasms, Multiple Primary / genetics. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / prevention & control. Ovariectomy. Ovary / drug effects. Ovary / pathology. Risk Factors

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19440148.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


48. Ishikura K, Takamura T, Takeshita Y, Nakagawa A, Imaizumi N, Misu H, Taji K, Kasahara K, Oshinoya Y, Suzuki S, Ooi A, Kaneko S: Cushing's syndrome and big IGF-II associated hypoglycaemia in a patient with adrenocortical carcinoma. BMJ Case Rep; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cushing's syndrome and big IGF-II associated hypoglycaemia in a patient with adrenocortical carcinoma.
  • A 41-year-old woman had a general health examination and was diagnosed with a non-functioning adrenocortical carcinoma (ACC).
  • Initially, she developed adrenal insufficiency and was treated with hydrocortisone.
  • She had to be given large quantities of glucose intravenously to remain normoglycaemic.
  • We identified big IGF-II, a primary hormonal mediator of non-islet cell tumour hypoglycaemia (NICTH), in the serum and tumour using western blotting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22461853.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027795
  •  go-up   go-down


49. Basu S, Kung J, Houseni M, Zhuang H, Tidmarsh GF, Alavi A: Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions. Q J Nucl Med Mol Imaging; 2009 Feb;53(1):9-19
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions.
  • AIM: In this study, the fluorodeoxyglucose (FDG) uptake was prospectively investigated in tumors as well as the normal organs over 8 h in patients with non small cell lung carcinoma (NSCLC).
  • METHODS: Three patients (2 males, 1 female; mean age: 64 years; age range: 57-76 years) with the diagnosis of NSCLC underwent a series of whole body FDG-PET at several time points, beginning at 5 min and extending up to 8 h after the intravenous administration of FDG.
  • 5) large bowel: 2.1, 1.4, 1.8, 1.4, 2, 2.2;.
  • 10) adrenal metastasis (starting at 1 h): 3.3, 3.7, 4.7, 4.7, 4.7;.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / pathology. Fluorodeoxyglucose F18 / pharmacokinetics. Lung / metabolism. Lung Neoplasms / metabolism. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18337683.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


50. Van Schil PE, Hendriks JM, Carp L, Lauwers PR: Surgery for oligometastatic disease in non-small-cell lung cancer. Expert Rev Anticancer Ther; 2008 Dec;8(12):1931-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery for oligometastatic disease in non-small-cell lung cancer.
  • In general, patients with additional metastatic nodules or distant metastases of a non-small-cell lung cancer (NSCLC) have a poor prognosis.
  • However, published results suggest that in carefully selected patients with synchronous or metachronous metastatic lesions, long-term survival can be obtained when a complete resection of the primary site and metastasis - mostly single brain or adrenal - is achieved.
  • In view of recent data from a large, international database, proposals have been made for the new TNM classification that will be introduced in 2009.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046113.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 21
  •  go-up   go-down


51. Cerquetti L, Bucci B, Marchese R, Misiti S, De Paula U, Miceli R, Muleti A, Amendola D, Piergrossi P, Brunetti E, Toscano V, Stigliano A: Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Endocr Relat Cancer; 2008 Jun;15(2):623-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
  • This drug and radiotherapy are used also in adrenal cancer treatment even if their biological action in this neoplasia remains unknown.
  • We investigated the effects of o,p'-DDD and ionizing radiations (IR) on cell growth inhibition and cell cycle perturbation in H295R and SW13 adrenocortical cancer cells.
  • Both cell lines were irradiated at a 6 Gy dose and were treated with o,p'-DDD 10(-5) M separately and with IR/o,p'-DDD in combination.
  • This combination treatment induced an irreversible inhibition of cell growth in both adrenocortical cancer cells.
  • Cell cycle analysis showed that IR alone and IR/o,p'-DDD in combination induced the cell accumulation in the G2 phase.
  • In order to study the molecular mechanism involved in the G2 irreversible arrest, we have considered the H295R cell line showing the highest inhibition of cell proliferation associated with a noteworthy G2 arrest.
  • Moreover, in these cells, sequence analysis of p53 revealed a large deletion of exons 8 and 9.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Antineoplastic Agents, Hormonal / pharmacology. Mitotane / pharmacology. Radiotherapy
  • [MeSH-minor] CDC2 Protein Kinase / metabolism. Cell Division / drug effects. Cell Division / radiation effects. Cell Line, Tumor. Cyclin B / metabolism. Cyclin B1. G2 Phase / drug effects. G2 Phase / radiation effects. Humans. RNA, Messenger / metabolism. Steroids / pharmacology. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. MITOTANE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18509009.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / CCNB1 protein, human; 0 / Cyclin B; 0 / Cyclin B1; 0 / RNA, Messenger; 0 / Steroids; 0 / Tumor Suppressor Protein p53; 78E4J5IB5J / Mitotane; EC 2.7.11.22 / CDC2 Protein Kinase
  •  go-up   go-down


52. Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, Sabatier L, Dartevelle P, Taranchon E, Besse B, Validire P, Italiano A, Soria JC: Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol; 2009 Oct;4(10):1212-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.
  • The correlation of biomarker expression between the primary tumor and its corresponding metastasis has not yet been well documented and analyzed in patients with non-small cell lung cancer (NSCLC).
  • The ERCC1 status was discordant in 20 cases (41%), with a trend toward overexpression in brain and adrenal metastases (p = 0.01 and p = 0.08, respectively).
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Biomarkers, Tumor / metabolism. Bone Neoplasms / metabolism. Brain Neoplasms / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. DNA-Binding Proteins / metabolism. Endonucleases / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Receptors, Vascular Endothelial Growth Factor / metabolism. Survival Rate. Vascular Endothelial Growth Factor A / metabolism


53. Daniele L, Cassoni P, Bacillo E, Cappia S, Righi L, Volante M, Tondat F, Inghirami G, Sapino A, Scagliotti GV, Papotti M, Novello S: Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol; 2009 Jun;4(6):684-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer.
  • INTRODUCTION: The majority of patients with non-small cell lung cancer (NSCLC) develop distant metastases.
  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are capable of reducing brain and adrenal metastases.
  • METHODS: Using fluorescence in situ hybridization (FISH) analysis, the EGFR gene status was evaluated in a series of 38 cerebral or adrenal metastases collected from two institutions and in the corresponding primary tumors.
  • Among the seven cases FISH-positive at the metastatic site but negative in the primary tumor, six were brain metastases, and one was an adrenal metastasis; all were polysomic for chromosome 7, none were amplified.
  • CONCLUSION: Because the molecular asset of EGFR may change during the metastatic progression of NSCLC to brain (but not to adrenal), the selection of patients with brain metastasis for specific targeted therapies by EGFR FISH analysis should be performed on metastatic lesions rather than on their corresponding primary tumors.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Brain Neoplasms / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Chromosomes, Human, Pair 7 / genetics. DNA, Neoplasm / genetics. DNA, Neoplasm / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Small Cell Lung Carcinoma / genetics. Small Cell Lung Carcinoma / secondary. Survival Rate


54. Waldmann J, Feldmann G, Slater EP, Langer P, Buchholz M, Ramaswamy A, Saeger W, Rothmund M, Fendrich V: Expression of the zinc-finger transcription factor Snail in adrenocortical carcinoma is associated with decreased survival. Br J Cancer; 2008 Dec 2;99(11):1900-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the zinc-finger transcription factor Snail in adrenocortical carcinoma is associated with decreased survival.
  • In conclusion, we describe for the first time that Snail is expressed in a large subset of ACCs.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / metabolism. Biomarkers, Tumor / analysis. Transcription Factors / biosynthesis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1998 Mar 12;392(6672):190-3 [9515965.001]
  • [Cites] Horm Res. 1997;47(4-6):279-83 [9167965.001]
  • [Cites] Physiol Rev. 1959 Jan;39(1):162-82 [13623432.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):252-8 [15668718.001]
  • [Cites] Dig Dis Sci. 2005 Jan;50(1):42-6 [15712635.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Cell Cycle. 2005 Jun;4(6):772-6 [15917668.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7622-7 [16140927.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):548-58 [16098727.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):197-209 [16169465.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] Eur J Endocrinol. 2006 Apr;154(4):587-98 [16556722.001]
  • [Cites] Oncol Rep. 2006 Jul;16(1):65-71 [16786124.001]
  • [Cites] Jpn J Clin Oncol. 2006 Jun;36(6):357-63 [16766568.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5395-402 [17000672.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):148-54 [17062775.001]
  • [Cites] Breast Cancer Res. 2006;8(4):105 [16834762.001]
  • [Cites] Endocr Pathol. 2006 Winter;17(4):345-54 [17525483.001]
  • [Cites] Histopathology. 2007 Aug;51(2):239-45 [17593212.001]
  • [Cites] Endocr Relat Cancer. 2007 Sep;14(3):865-74 [17914115.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):711-36 [10679640.001]
  • [Cites] Mol Cell. 2001 Jun;7(6):1267-78 [11430829.001]
  • [Cites] Eur J Endocrinol. 2001 Sep;145(3):335-41 [11517015.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1113-21 [11571723.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1613-8 [11912130.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):521-31 [12547710.001]
  • [Cites] Am J Clin Pathol. 2004 Jul;122(1):78-84 [15272533.001]
  • [Cites] Development. 2004 Sep;131(17):4213-24 [15280211.001]
  • [Cites] Nat Cell Biol. 2004 Oct;6(10):931-40 [15448698.001]
  • [Cites] Am J Clin Pathol. 1979 Sep;72(3):390-9 [474519.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Endocrinology. 1990 Jun;126(6):3251-62 [2161753.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1303-9 [9137490.001]
  • [Cites] Horm Metab Res. 1998 Jun-Jul;30(6-7):421-5 [9694573.001]
  • (PMID = 19018264.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / snail family transcription factors
  • [Other-IDs] NLM/ PMC2600683
  •  go-up   go-down


55. Børglum T, Rehfeld JF, Drivsholm LB, Hilsted L: Processing-independent quantitation of chromogranin a in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas. Clin Chem; 2007 Mar;53(3):438-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Processing-independent quantitation of chromogranin a in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas.
  • To cope with this variability and improve tumor diagnosis, we developed a processing-independent analysis (PIA) method to measure the total CgA product.
  • The diagnostic accuracy of the CgA PIA and 3 sequence-specific assays for CgA were evaluated on plasma samples from patients with neuroendocrine tumors and small-cell lung carcinomas.
  • RESULTS: Size-exclusion chromatography of plasma showed that CgA immunoreactivity mainly consisted of high-molecular-weight forms, indicating that neuroendocrine tumors may secrete large amounts of poorly processed CgA.
  • Accordingly, trypsination of plasma from 54 patients with neuroendocrine tumors or small-cell lung carcinomas increased the CgA(340-->) immunoreactivity up to 500-fold.
  • CONCLUSION: The CgA(340-->) assay and CgA PIA are both useful for diagnosis of neuroendocrine tumors and small-cell lung carcinomas and both assays correlate with tumor burden.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Chromogranin A / blood. Gastrointestinal Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Neuroendocrine Tumors / diagnosis
  • [MeSH-minor] Adrenal Gland Neoplasms / diagnosis. Adult. Aged. Diagnosis, Differential. Female. Humans. Immunoassay. Male. Middle Aged. Pheochromocytoma / diagnosis. Plasma. Reference Values. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17259235.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranin A
  •  go-up   go-down


56. Fukuda I, Hizuka N, Ishikawa Y, Yasumoto K, Murakami Y, Sata A, Morita J, Kurimoto M, Okubo Y, Takano K: Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Horm IGF Res; 2006 Aug;16(4):211-6
MedlinePlus Health Information. consumer health - Hypoglycemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia.
  • In some patients with non-islet-cell tumor hypoglycemia (NICTH), a high molecular weight form of IGF-II (big IGF-II) derived from tumors is present in the circulation and might be associated with recurrent hypoglycemia.
  • In this study, in order to survey the clinical characteristics of patients with IGF-II producing NICTH, we analyzed the medical records of 78 patients with NICTH (M/F 44/34, age 62+/-1.8, range; 9-86 years.) whose serum contained a large amount of big IGF-II.
  • Hepatocellular carcinoma and gastric carcinoma were the most common causes of NICTH.
  • These data suggested that hypoinsulinemic hypoglycemia associated with the presence of a large tumor supports the diagnosis of IGF-II producing NICTH.
  • [MeSH-minor] Adolescent. Adrenal Gland Neoplasms / secretion. Adult. Aged. Aged, 80 and over. Blood Glucose / analysis. Breast Neoplasms / secretion. Carcinoma, Hepatocellular / secretion. Carcinoma, Renal Cell / secretion. Child. Female. Fibrosarcoma / secretion. Gastrointestinal Stromal Tumors / secretion. Humans. Insulin-Like Growth Factor I / analysis. Insulin-Like Growth Factor II. Leiomyosarcoma / secretion. Liver Neoplasms / secretion. Male. Middle Aged. Pancreatic Neoplasms / secretion. Pheochromocytoma / secretion. Prostatic Neoplasms / secretion. Retrospective Studies. Stomach Neoplasms / secretion

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • Genetic Alliance. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860583.001).
  • [ISSN] 1096-6374
  • [Journal-full-title] Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • [ISO-abbreviation] Growth Horm. IGF Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / IGF2 protein, human; 0 / Proteins; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


57. Hamanaka W, Yoneda S, Shirakusa T, Shirahama H, Tashiro Y, Iwasaki A, Shiraishi T, Tsuru H: Alpha-fetoprotein (AFP)-producing adrenocortical carcinoma--long survival with various therapeutic strategies including a lung resection: report of a case. Surg Today; 2008;38(3):275-8
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-fetoprotein (AFP)-producing adrenocortical carcinoma--long survival with various therapeutic strategies including a lung resection: report of a case.
  • Instead of a large metastatic lung tumor with hemothorax and the existence of metastases in other organs, combined therapy of repeated resections for metastases and adjuvant therapy allowed for almost a 36-month survival following the first recurrence and a good quality of life.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenal Cortex Neoplasms / mortality. Adrenocortical Carcinoma / metabolism. Adrenocortical Carcinoma / mortality. alpha-Fetoproteins / biosynthesis
  • [MeSH-minor] Adult. Brain Neoplasms / secondary. Cell Nucleus / metabolism. Cytoplasm / metabolism. Female. Humans. Immunohistochemistry. Kidney Neoplasms / secondary. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Pneumonectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1990 Apr 26;322(17):1195-201 [2325710.001]
  • [Cites] Surgery. 1986 Dec;100(6):1170-7 [3787475.001]
  • [Cites] Int J Urol. 2003 Aug;10(8):445-8 [12887367.001]
  • [Cites] Surgery. 1992 Dec;112(6):963-70; discussion 970-1 [1455321.001]
  • [Cites] CA Cancer J Clin. 1987 Nov-Dec;37(6):348-65 [3119168.001]
  • [Cites] Cancer. 2002 May 1;94(9):2333-43 [12015757.001]
  • [Cites] Surgery. 1995 Dec;118(6):1090-8 [7491528.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] J Natl Med Assoc. 2001 Jan;93(1):37-9 [12653379.001]
  • [Cites] Arch Surg. 1991 Apr;126(4):457-61 [1706914.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):161-5 [8418229.001]
  • [Cites] Surgery. 1991 Dec;110(6):1006-13 [1745969.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1281-7 [11106117.001]
  • [Cites] World J Surg. 2001 Jun;25(6):735-8 [11376408.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3145-55 [8242539.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):2929-31 [12926137.001]
  • [Cites] Surgery. 1996 Feb;119(2):161-70 [8571201.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):941-50 [11844815.001]
  • [Cites] Hinyokika Kiyo. 1994 May;40(5):411-4 [7517622.001]
  • [Cites] World J Surg. 2004 Sep;28(9):896-903 [15593464.001]
  • (PMID = 18307006.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


58. Kim SS, Peng LF, Lin W, Choe WH, Sakamoto N, Kato N, Ikeda M, Schreiber SL, Chung RT: A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology; 2007 Jan;132(1):311-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication.
  • METHODS: We first optimized the Huh7/Rep-Feo replicon cell line for the 384-well microplate format and used this line to screen a large library of well-characterized, known biologically active compounds using automated technology.
  • After identifying several molecules capable of either stimulating or inhibiting HCV replication in this primary screen, we then validated our hit compounds using a full-length HCV replicon cell line in secondary screens.
  • CONCLUSIONS: We have developed a simple, reproducible, and reliable cell-based high-throughput screening assay system using an HCV replicon model to identify small molecules that regulate HCV replication.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Gastroenterology. 2007 Aug;133(2):730
  • [ErratumIn] Gastroenterology. 2007 May;132(5):2082
  • [ErratumIn] Gastroenterology. 2007 Mar;132(3):1208. Kato, Nobuyuki [added]; Ikeda, Masanori [added]
  • (PMID = 17241881.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK088951; United States / NIDDK NIH HHS / DK / 5T32 DK 07191-31; United States / NINDS NIH HHS / NS / NS 050854-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antiviral Agents; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
  •  go-up   go-down


59. Kinlaw WB, Scott SM, Maue RA, Memoli VA, Harris RD, Daniels GH, Porter DM, Belloni DR, Spooner ET, Ernesti MM, Noll WW: Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma. Clin Endocrinol (Oxf); 2005 Dec;63(6):676-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
  • OBJECTIVE: We have identified a large kindred with multiple endocrine neoplasia 2A (MEN 2A) due to a mutation at RET codon 609 that results in a cysteine to serine substitution, a mutation previously identified in only one case in the literature.
  • Of the 15 mutation-positive family members, 11 agreed to undergo further evaluation by physical examination, calcium and pentagastrin-stimulated calcitonin levels, measurement of urinary metanephrines, adrenal imaging and serum calcium levels.
  • Thyroidectomy in six cases revealed C-cell hyperplasia in all and microscopic MTC in two cases.
  • [MeSH-major] Carcinoma, Medullary / genetics. Multiple Endocrine Neoplasia Type 2a / diagnosis. Pheochromocytoma / genetics. Point Mutation. Proto-Oncogene Proteins c-ret / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Calcitonin / blood. Calcium. Catecholamines / urine. Child. Codon. Female. Humans. Male. Metanephrine / urine. Middle Aged. Pedigree. Pentagastrin. Polymorphism, Restriction Fragment Length. Sequence Analysis, DNA. Thyroid Gland / pathology. Vanilmandelic Acid / urine


60. Li F, Zhong Z, Li R, Huang H, Wang L, Zheng D, Zhang D: [Expression and clinicopathologic significance of human achaete-scute homolog 1 in pulmonary neuroendocrine tumors]. Zhongguo Fei Ai Za Zhi; 2010 Apr;13(4):317-21
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVE: Human achaete-scute homolog 1 (hASH1) gene plays a critical role in development of the central nervous system, automatic nervous system, adrenal medullary chromaffin cells, thyroid C cells and pulmonary neuroendocrine cells.
  • METHODS: hASH1, Chromogranin A, Synaptophysin and CD56 expression were examined in lung tumor specimens (lung inflammatory pseudotumor, squamous cell carcinoma, adenocarcinomas, large cell carcinoma, typical carcinoids, atypical carcinoids, large cell neuroendocrine carcinomas and small cell lung carcinoma and corresponding normal lung specimens) using immunohistochemistry (S-P method).
  • RESULTS: hASH1 expression was positive in 2/16 (12.5%) typical carcinoids, 15/20 (75%) atypical carcinoids, 6/10 (60%) large cell neuroendocrine carcinomas and 31/40 (77.5%) small cell lung carcinoma, respectively, but not in any normal lung tissue (0/10), lung inflammatory pseudotumor (0/49), squamous cell carcinoma (0/30), adenocarcinomas (0/30) or large cell carcinoma (0/20).
  • There was a significant difference in hASH1 expression between typical carcinoids and atypical carcinoids (P < 0.01), but not in large cell neuroendocrine carcinomas and small cell lung carcinoma (P > 0.05).
  • CONCLUSION: hASH1 is a new kind of highly specific markers of pulmonary neuroendocrine tumours, and may be applied to clinical pathology diagnosis of the pulmonary neuroendocrine tumors.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Neuroendocrine / genetics. Carcinoma, Neuroendocrine / metabolism. Carcinoma, Neuroendocrine / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Gene Expression Regulation, Neoplastic / genetics. Gene Expression Regulation, Neoplastic / physiology. Humans. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction. Small Cell Lung Carcinoma / genetics. Small Cell Lung Carcinoma / metabolism. Small Cell Lung Carcinoma / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677557.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ASCL1 protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors
  •  go-up   go-down


61. Barzon L, Pacenti M, Masi G, Stefani AL, Fincati K, Palù G: Loss of growth hormone secretagogue receptor 1a and overexpression of type 1b receptor transcripts in human adrenocortical tumors. Oncology; 2005;68(4-6):414-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE AND METHODS: Quantitative analysis of mRNA expression of ghrelin and its receptors GHS-R1a and -R1b in a large series of normal and neoplastic human adrenocortical tissues.
  • Evaluation of the effects of ghrelin on GHS-R expression and proliferation of human adrenocortical carcinoma (ACC) cell lines.
  • RESULTS: Ghrelin and GHS-R transcripts are expressed in normal adrenal cortex, with GHS-R1b mRNA levels being 5- to 10-fold higher than GHS-R1amRNA.
  • In vitro studies in human ACC cell lines demonstrated that GHS-R1a is downregulated and GHS-R1bmRNA expression is upregulated by ghrelin, while inhibiting cell proliferation.
  • CONCLUSION: Downregulation ofGHS-R1a in adrenal tumors and the presence of high levels of GHS-R1b transcripts in adrenocortical tissue suggest a role for these receptors in adrenal function and growth.
  • In this regard, ghrelin inhibits cell proliferation and modulates GHS-R expression in ACC cells in vitro.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocortical Adenoma / metabolism. Adrenocortical Carcinoma / metabolism. Gene Expression Regulation, Neoplastic. Receptors, G-Protein-Coupled / metabolism
  • [MeSH-minor] Adrenal Cortex / metabolism. Cell Proliferation. Ghrelin. Growth Hormone / pharmacology. Humans. Peptide Hormones / pharmacology. Peptides / genetics. Peptides / metabolism. RNA, Messenger. Receptors, Ghrelin. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 S. Karger AG, Basel
  • (PMID = 16020971.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Ghrelin; 0 / Peptide Hormones; 0 / Peptides; 0 / RNA, Messenger; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Ghrelin; 9002-72-6 / Growth Hormone
  •  go-up   go-down


62. Rindi G, Licini L, Necchi V, Bottarelli L, Campanini N, Azzoni C, Favret M, Giordano G, D'Amato F, Brancia C, Solcia E, Ferri GL: Peptide products of the neurotrophin-inducible gene vgf are produced in human neuroendocrine cells from early development and increase in hyperplasia and neoplasia. J Clin Endocrinol Metab; 2007 Jul;92(7):2811-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: proVGF fragments were revealed in developing pituitary, gut, pancreas, and adrenal medulla from 10 gestational weeks, in normal adult pituitary and adrenal medulla, pancreatic glucagon, and insulin cells and gut serotonin cells, in hyperplastic thyroid calcitonin cells, lung P cells, gastric enterochromaffin-like cells, and gastrin cells, and in 88 of 102 endocrine tumors.
  • Western blotting revealed large molecular weight forms and cleavage fragments in both control tissues and tumor extracts.
  • [MeSH-major] Adenoma / metabolism. Adenoma / pathology. Endocrine Gland Neoplasms / metabolism. Endocrine Gland Neoplasms / pathology. Nerve Growth Factors / metabolism
  • [MeSH-minor] Adrenal Gland Neoplasms / metabolism. Adrenal Gland Neoplasms / pathology. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Small Cell / metabolism. Carcinoma, Small Cell / pathology. Cell Differentiation. Endocrine System / growth & development. Endocrine System / metabolism. Endocrine System / pathology. Gastrointestinal Neoplasms / metabolism. Gastrointestinal Neoplasms / pathology. Humans. Hyperplasia. Paraganglioma / metabolism. Paraganglioma / pathology. Pheochromocytoma / metabolism. Pheochromocytoma / pathology

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440014.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nerve Growth Factors; 0 / VGF protein, human
  •  go-up   go-down


63. Campagnacci R, Guerrieri M, De Sanctis A, Sarnari J, Lezoche E: Laparoscopic radiofrequency renal ablation in patients with simultaneous visceral tumors: long-term follow-up. J Endourol; 2006 May;20(5):321-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: From September 2000 to May 2002, two men, 81 and 71 years old, and one woman, 75 years old, were referred to our department for right renal clear-cell carcinoma <3.5-cm diameter.
  • Moreover, a simultaneous large right adrenal incidentaloma (myelolipoma) and a right colon cancer were known to be present in the second and third patient, respectively.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16724903.001).
  • [ISSN] 0892-7790
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Wright CB, Brennan L, Brophy P, Kirsh G, Shapiro M, Potter B, Giss S, Lindeman KE, Obial R, Fannin E: Adrenocortical tumor with left renal vein, vena cava and intrahepatic venous extension. J Cardiovasc Surg (Torino); 2008 Feb;49(1):79-81
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 41 year old white female presented with upper respiratory distress and shortness of breath appeared on initial computed tomography (CT) scan to have a large left retroperitoneal mass with left renal vein extension including a mass up to the level of the atrium.
  • She proved, however, to have an adrenal cortical carcinoma which displaced the kidney, exhibiting vascular invasion within the gland and non-adherent extension into the vena cava, atrium, common hepatic vein and left renal vein, where some adherence was present.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Carcinoma, Renal Cell / diagnosis. Hepatic Veins / pathology. Kidney Neoplasms / diagnosis. Renal Veins / pathology. Vena Cava, Inferior / pathology
  • [MeSH-minor] Adrenalectomy. Adult. Cardiopulmonary Bypass. Diagnosis, Differential. Female. Heart Atria / pathology. Humans. Neoplasm Invasiveness. Nephrectomy. Treatment Outcome. Vascular Surgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212691.001).
  • [ISSN] 0021-9509
  • [Journal-full-title] The Journal of cardiovascular surgery
  • [ISO-abbreviation] J Cardiovasc Surg (Torino)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


65. Tam V, Ng KF, Fung LM, Wong YY, Chan MH, Lam CW, Tam S, Lam CW: The importance of the interpretation of urine catecholamines is essential for the diagnosis and management of patient with dopamine-secreting paraganglioma. Ann Clin Biochem; 2005 Jan;42(Pt 1):73-7
Hazardous Substances Data Bank. DOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of the interpretation of urine catecholamines is essential for the diagnosis and management of patient with dopamine-secreting paraganglioma.
  • This case illustrates its atypical presentation and the importance of interpretative reporting for urine catecholamines leading to the diagnosis and subsequent management of a patient with this condition.
  • We report a 71-year-old Chinese woman with a large dopamine-secreting paraganglioma.
  • Good communication between chemical pathologists and physicians prompted the arrangement of the whole body 131I-meta-iodobenzylguanidine (MIBG) scintigraphy, which showed a large signal in the right upper quadrant of the abdomen corresponding to a large extra-adrenal tumour detected by both ultrasonography and computerized tomography (CT) of the abdomen.
  • Fine-needle aspiration cytology using the thoracoscopic technique was performed and immunochemical staining of the biopsy specimen showed the presence of non- small-cell carcinoma of the lung.
  • [MeSH-major] Dopamine / secretion. Epinephrine / urine. Norepinephrine / urine. Paraganglioma / diagnosis
  • [MeSH-minor] 3-Iodobenzylguanidine. Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / secretion. Aged. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / secondary. Carcinoma, Non-Small-Cell Lung / secretion. Female. Humans. Iodine Radioisotopes. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lung Neoplasms / secretion. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15802039.001).
  • [ISSN] 0004-5632
  • [Journal-full-title] Annals of clinical biochemistry
  • [ISO-abbreviation] Ann. Clin. Biochem.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 35MRW7B4AD / 3-Iodobenzylguanidine; VTD58H1Z2X / Dopamine; X4W3ENH1CV / Norepinephrine; YKH834O4BH / Epinephrine
  •  go-up   go-down


66. Barzon L, Masi G, Pacenti M, Trevisan M, Fallo F, Remo A, Martignoni G, Montanaro D, Pezzi V, Palù G: Expression of aromatase and estrogen receptors in human adrenocortical tumors. Virchows Arch; 2008 Feb;452(2):181-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recently demonstrated that adrenocortical carcinoma cells express aromatase and estrogen receptors (ERs) and that 17beta-estradiol enhances adrenocortical cell proliferation.
  • To provide a clue to the role of estrogens in adrenal tumorigenesis, we investigated the expression profile of genes involved in sex steroid hormone production and activity in a large series of normal and neoplastic human adrenocortical tissues.
  • Quantitative reverse transcriptase-polymerase chain reaction, Western blotting, and immunohistochemistry showed that ERalpha and ERbeta, androgen receptor (AR), and aromatase were expressed in the adrenal cortex and in adrenocortical tumors.
  • With respect to the normal adrenal cortex and adrenocortical adenomas, carcinomas were characterized by significantly lower ERbeta levels, ERalpha upregulation, and aromatase overexpression.
  • In agreement with our in vitro findings, the results of this study suggest that estrogens, locally produced by aromatase, could enhance adrenocortical cell proliferation though autocrine/paracrine mechanisms.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocortical Adenoma / metabolism. Adrenocortical Carcinoma / metabolism. Aromatase / metabolism. Receptors, Estrogen / metabolism
  • [MeSH-minor] Adrenal Cortex / embryology. Adrenal Cortex / metabolism. Adult. Aged. Biomarkers, Tumor / metabolism. Blotting, Western. Female. Gene Expression. Humans. Male. Middle Aged. RNA, Messenger / metabolism. RNA, Neoplasm / analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Virchows Arch. 2008 Aug;453(2):221-2 [18553103.001]
  • [Cites] Eur J Endocrinol. 2002 Dec;147(6):795-802 [12457455.001]
  • [Cites] J Mol Endocrinol. 2005 Oct;35(2):245-56 [16216906.001]
  • [Cites] Endocrinology. 2005 Dec;146(12 ):5474-84 [16150902.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jun;92(6):2215-22 [17405842.001]
  • [Cites] J Endocrinol Invest. 2005 May;28(5):459-63 [16075931.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Nov;87(2-3):181-9 [14672738.001]
  • [Cites] J Biol Chem. 2002 Jun 7;277(23):20591-7 [11927588.001]
  • [Cites] Comp Biochem Physiol B Biochem Mol Biol. 1997 Sep;118(1):217-27 [9418012.001]
  • [Cites] J Biol Chem. 1999 Jan 1;274(1):345-53 [9867849.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):327-34 [16728566.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Oct;82(10):3509-12 [9329394.001]
  • [Cites] Mol Genet Metab. 2001 Sep-Oct;74(1-2):206-16 [11592817.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):847-52 [10690900.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1612-9 [12459628.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9001-5 [17909000.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36418-29 [12842887.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Aug;80(8):2378-80 [7629233.001]
  • [Cites] Endocrinology. 2002 Mar;143(3):853-67 [11861507.001]
  • [Cites] Mol Endocrinol. 2002 Mar;16(3):515-28 [11875111.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):537-51 [15369453.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2258-62 [11344236.001]
  • [Cites] J Steroid Biochem. 1986 Jul;25(1):1-9 [3747509.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):657-63 [15695411.001]
  • [Cites] J Endocrinol. 2002 Sep;174(3):R13-7 [12208674.001]
  • [Cites] J Biol Chem. 2000 Dec 22;275(51):39855-9 [11053406.001]
  • [Cites] Mol Endocrinol. 2006 Oct;20(10):2326-42 [16709599.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):3010-9 [15181092.001]
  • [Cites] J Endocrinol. 1998 Dec;159(3):373-80 [9834454.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jul;83(7):2597-600 [9661652.001]
  • [Cites] Am J Obstet Gynecol. 1984 Oct 1;150(3):326-7 [6486196.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Dec;83(12 ):4520-3 [9851803.001]
  • [Cites] Eur J Endocrinol. 2003 Oct;149(4):273-85 [14514341.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):649-52 [11158024.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):432-6 [8621222.001]
  • [Cites] Mol Cell Endocrinol. 1991 Jun;78(1-2):25-32 [1936523.001]
  • [Cites] Oncogene. 2005 Dec 8;24(55):8167-75 [16091743.001]
  • (PMID = 18157729.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Estrogen; EC 1.14.14.1 / Aromatase
  •  go-up   go-down


67. Shen KR, Meyers BF, Larner JM, Jones DR, American College of Chest Physicians: Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest; 2007 Sep;132(3 Suppl):290S-305S
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: This chapter of the guidelines addresses patients who have particular forms of non-small cell lung cancer that require special considerations.
  • This includes patients with Pancoast tumors, T4N0,1M0 tumors, satellite nodules in the same lobe, synchronous and metachronous multiple primary lung cancers (MPLCs), solitary brain and adrenal metastases, and chest wall involvement.
  • METHODS: The nature of these special clinical cases is such that in most cases, metaanalyses or large prospective studies of patients are not available.
  • Selected patients with a solitary focus of metastatic disease in the brain or adrenal gland seem to benefit substantially from resection.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy. Neoplasms, Multiple Primary / therapy. Pancoast Syndrome / therapy
  • [MeSH-minor] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / therapy. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Combined Modality Therapy. Evidence-Based Medicine. Humans. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17873175.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] United States
  •  go-up   go-down


68. Kelleher FC, McDermott R: The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. Eur J Cancer; 2010 Sep;46(13):2357-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This gene was originally established as being implicated in the pathogenesis of rare diseases including inflammatory myofibroblastic tumour (IMT) and ALK-positive anaplastic large cell lymphoma, which is a subtype of non-Hodgkin's lymphoma.
  • In 2007, an inversion of chromosome 2 involving ALK and a fusion partner gene in a subset of non-small cell lung cancer was discovered.
  • In 2008, publications emerged implicating ALK in familial and sporadic cases of neuroblastoma, a childhood cancer of the sympatho-adrenal system.
  • This has been described in ALK-positive anaplastic large cell lymphoma in which ALK is fused to NPM (nucleolar protein gene) and in non-small cell lung cancer where ALK is fused to EML4 (Echinoderm microtubule-associated protein 4).
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / therapy. Drug Synergism. Gene Amplification. Humans. Lung Neoplasms / genetics. Lung Neoplasms / therapy. Lymphoma, Large-Cell, Anaplastic / genetics. Lymphoma, Large-Cell, Anaplastic / therapy. Mutation / genetics. Neuroblastoma / genetics. Neuroblastoma / therapy. Pyrimidines / therapeutic use. Pyrroles / therapeutic use. Receptor Protein-Tyrosine Kinases. Receptor, IGF Type 1 / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20451371.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / GSK 1838705A; 0 / Pyrimidines; 0 / Pyrroles; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


69. Greene FL, Kercher KW, Nelson H, Teigland CM, Boller AM: Minimal access cancer management. CA Cancer J Clin; 2007 May-Jun;57(3):130-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Minimal access approaches in the treatment of a variety of solid tumors of the stomach, large bowel, and genitourinary system are now being advocated in several surgical specialty areas.
  • Caution, however, should be exercised in recommending laparoscopic approaches for routine management of primary tumors of the rectum and adrenal gland.
  • [MeSH-minor] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Carcinoma, Renal Cell / surgery. Colectomy / methods. Colectomy / mortality. Colonic Neoplasms / surgery. Humans. Kidney Neoplasms / surgery. Minimally Invasive Surgical Procedures. Rectal Neoplasms / surgery. Stomach Neoplasms / surgery. Treatment Outcome. Urogenital Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] CA Cancer J Clin. 2007 Sep-Oct;57(5):300
  • (PMID = 17507440.001).
  • [ISSN] 0007-9235
  • [Journal-full-title] CA: a cancer journal for clinicians
  • [ISO-abbreviation] CA Cancer J Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 96
  •  go-up   go-down


70. McNeill A, Rattenberry E, Barber R, Killick P, MacDonald F, Maher ER: Genotype-phenotype correlations in VHL exon deletions. Am J Med Genet A; 2009 Oct;149A(10):2147-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Type 2 subtypes of VHL syndrome are characterized by the presence of pheochromocytoma and the three Type 2 subtypes are associated with differing risks of hemangioblastoma and renal cell carcinoma (RCC).
  • Recently, it has been suggested that large VHL gene deletions involving C3orf10 (HSPC300) might be associated with a low risk of RCC.
  • Large VHL gene deletions associated with a contiguous loss of C3orf10 were associated with a significantly lower lifetime risk of RCC than deletions that did not involve C3orf10.
  • These results add to the growing body of evidence suggesting that patients with VHL syndrome caused by large VHL deletions that include C3orf10 may be designated as having a specific subtype (Type 1B) of the disorder.
  • [MeSH-minor] Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / genetics. Carcinoma, Renal Cell / complications. Carcinoma, Renal Cell / genetics. Cerebellar Neoplasms / complications. Cerebellar Neoplasms / genetics. Cytoskeletal Proteins / genetics. DNA Mutational Analysis. Exons / genetics. Fanconi Anemia Complementation Group D2 Protein / genetics. Genotype. Germ-Line Mutation. Hemangioblastoma / complications. Hemangioblastoma / genetics. Humans. Kidney Neoplasms / complications. Kidney Neoplasms / genetics. Pheochromocytoma / complications. Pheochromocytoma / genetics. Retinal Neoplasms / complications. Retinal Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764026.001).
  • [ISSN] 1552-4833
  • [Journal-full-title] American journal of medical genetics. Part A
  • [ISO-abbreviation] Am. J. Med. Genet. A
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRK1 protein, human; 0 / Cytoskeletal Proteins; 0 / FANCD2 protein, human; 0 / Fanconi Anemia Complementation Group D2 Protein; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


71. Lin TY, Chou YY, Hsiao FC, Wang YC, Chang PY, Yao NS: Lung cancer metastatic to the masticator space. Onkologie; 2009 Jun;32(6):349-51
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Distant metastasis from lung cancer occurs most frequently to the brain, bone, adrenal gland, liver, lymph nodes, and spinal cord.
  • CASE REPORT: We report a case of large cell neuroendocrine carcinoma of the lung with metastasis to the masticator space diagnosed by imaging and histopathological examinations.
  • CONCLUSION: The present case highlights the fact that large cell neuroendocrine carcinoma of the lung can result in an uncommon isolated masticator space metastasis.
  • Thorough dental and physical examination, and imaging studies could provide early diagnosis and treatment.
  • [MeSH-major] Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / secondary. Head and Neck Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19521123.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


72. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, Sanders D, Thomas DG, Doherty G, Hammer G: Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res; 2009 Jan 15;15(2):668-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Our understanding of adrenocortical carcinoma (ACC) has improved considerably, yet many unanswered questions remain.
  • EXPERIMENTAL DESIGN: We did a whole genome gene expression study of a large cohort of adrenocortical tissues annotated with clinicopathologic data.
  • Using Affymetrix Human Genome U133 Plus 2.0 oligonucleotide arrays, transcriptional profiles were generated for 10 normal adrenal cortices (NC), 22 adrenocortical adenomas (ACA), and 33 ACCs.
  • Cluster analysis of the ACCs revealed two subtypes that reflected tumor proliferation, as measured by mitotic counts and cell cycle genes.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1039-45 [10514385.001]
  • [Cites] World J Surg. 2004 Sep;28(9):896-903 [15593464.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1819-29 [15613424.001]
  • [Cites] Nat Genet. 2005 Jun;37(6):579-83 [15920519.001]
  • [Cites] Eur J Endocrinol. 2005 Oct;153(4):477-87 [16189167.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6646-56 [16007166.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Surgery. 2005 Dec;138(6):1087-94 [16360395.001]
  • [Cites] Eur J Endocrinol. 2006 Apr;154(4):587-98 [16556722.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1043-8 [16921376.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5079-90 [17075127.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Nov;2(11):632-41 [17082810.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D760-5 [17099226.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):148-54 [17062775.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):600-8 [17234769.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):1-12 [17237261.001]
  • [Cites] Endocr Rev. 2007 Feb;28(1):20-47 [16931767.001]
  • [Cites] Endocr Relat Cancer. 2007 Mar;14(1):13-28 [17395972.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):175-8 [17427106.001]
  • [Cites] APMIS. 2007 Apr;115(4):381-4 [17504308.001]
  • [Cites] Endocr Pathol. 2006 Winter;17(4):345-54 [17525483.001]
  • [Cites] Endocr Pathol. 2006 Winter;17(4):355-63 [17525484.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Oct;4(10):591-602 [17898809.001]
  • [Cites] Mol Cancer Ther. 2008 Feb;7(2):425-31 [18281524.001]
  • [Cites] Endocr J. 2008 Mar;55(1):49-55 [18187873.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1442-9 [18198226.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jun;28(2):145-52 [10824999.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1231-8 [11583950.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):941-50 [11844815.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1170-6 [11889182.001]
  • [Cites] Endocr Pathol. 2001 Winter;12(4):397-406 [11914473.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3467-74 [12107267.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1612-9 [12459628.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):521-31 [12547710.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6810-8 [14555994.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1985-95 [14578198.001]
  • [Cites] Eur J Endocrinol. 2004 Jun;150(6):809-17 [15191351.001]
  • [Cites] Horm Metab Res. 2004 Jun;36(6):397-405 [15241731.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4219-23 [8797595.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] J Mol Endocrinol. 1999 Aug;23(1):23-32 [10425444.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3246-8 [15180930.001]
  • (PMID = 19147773.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA046592-209023; United States / NCI NIH HHS / CA / CA046592-219023; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NCI NIH HHS / CA / CA046592-199023; United States / NCI NIH HHS / CA / P30 CA046592-219023; United States / NCI NIH HHS / CA / P30 CA046592-199023; United States / NCI NIH HHS / CA / P30 CA046592-209023
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin E
  • [Other-IDs] NLM/ NIHMS78831; NLM/ PMC2629378
  •  go-up   go-down


73. Wang Q, Huang LL, Yue MG, Qin SL, Wang Y, Nie YX, Zhang CQ, Liang TJ, Zhao YM: [18F-FDG imaging by coincidence circuit SPECT with low-dose CT in preoperative assessment of pulmonary lesions]. Zhonghua Zhong Liu Za Zhi; 2006 Dec;28(12):924-7
MedlinePlus Health Information. consumer health - Pneumonia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the clinical diagnostic value of 18F-FDG imaging by coincidence circuit SPECT with low-dose CT in differential diagnosis of pulmonary lesions and mediastinal lymph node involvement, which can not be definitely diagnosed based on regular CT image in patients with non-small-cell lung cancer (NSCLC).
  • RESULTS: Final pathologic diagnoses of these patients were 36 malignancies consisting of 20 adenocarcinomas, 12 squamous cell carcinomas, 3 small cell carcinomas and I large cell carcinoma; 12 benign tumors including 6 pneumonias, 2 tuberculosis, 2 hamatomas, 1 cyst and 1 neurofibroma.
  • Correct diagnosis were made in 34 malignancies and 6 false positive lesions were excluded based on morphology and 18F-FDG uptake status of the lesion.
  • Furthermore, extrathoracic metastases which were not showed on previous CT image in 4 patients including one in the adrenal gland and 3 in the bone were detected by 18F-FDG imaging.
  • Squamous cell carcinoma was found to uptake more FDG than adenocarcinoma.
  • CONCLUSION: 18F-FDG imaging by coincidence circuit SPECT with low-dose CT is quite helpful in differential diagnosis for patient with undetermined lesion on regular CT image, but it is limited for staging of lung cancer in the patients with non-small cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis. Pneumonia / diagnosis. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Lung / pathology. Lung / radiography. Lung / radionuclide imaging. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Radiation Dosage. Radiopharmaceuticals. Retrospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed. Tuberculosis, Pulmonary / diagnosis. Tuberculosis, Pulmonary / radiography. Tuberculosis, Pulmonary / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17533745.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


74. Schittenhelm J, Ebner FH, Harter P, Bornemann A: Symptomatic intraspinal oncocytic adrenocortical adenoma. Endocr Pathol; 2009;20(1):73-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The excised tumor was composed of nests of large polygonal cells with eosinophilic partial granular cytoplasm.
  • The diagnosis of an oncocytic adrenal cortical adenoma was made.
  • Oncocytic tumors are rare neoplasms and they comprise non-functioning variants of adrenal cortical adenomas.
  • Immunohistochemistry excluded oncocytic paraganglioma, oncocytic meningioma, renal cell carcinoma, alveolar soft part sarcoma, and granular cell tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19039533.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Ip YT, Yuan JQ, Cheung H, Chan JK: Sporadic hemangioblastoma of the kidney: an underrecognized pseudomalignant tumor? Am J Surg Pathol; 2010 Nov;34(11):1695-700
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, the tumors were circumscribed, and composed of sheets of large polygonal cells traversed by arborizing thin-walled blood vessels.
  • The diagnosis of hemangioblastoma was confirmed by negative immunostaining for cytokeratin, and positive staining for α-inhibin, S100, and neuron-specific enolase.
  • This benign neoplasm which can be mistaken for various malignancies such as renal cell carcinoma, epithelioid angiomyolipoma, adrenal cortical carcinoma, and paraganglioma, deserves wider recognition for its occurrence as a primary renal tumor.

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2011 Apr;35(4):623-4 [21378542.001]
  • (PMID = 20924277.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; 68238-35-7 / Keratins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


76. Gatta G, Ciccolallo L, Kunkler I, Capocaccia R, Berrino F, Coleman MP, De Angelis R, Faivre J, Lutz JM, Martinez C, Möller T, Sankila R, EUROCARE Working Group: Survival from rare cancer in adults: a population-based study. Lancet Oncol; 2006 Feb;7(2):132-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We aimed to study the epidemiology of rare cancers in a large population of several countries.
  • FINDINGS: Overall 5-year relative survival was good (ie, >65%) for placental choriocarcinoma (85.4% [95% CI 81.4-89.5]), thyroid medullary carcinoma (72.4% [69.2-75.5]), ovarian germ-cell cancer (73.0% [70.0-76.0]), lung carcinoid (70.1% [67.3-72.9]), and cervical adenocarcinoma (65.5% [64.3-66.6]); intermediate (ie, 35-65%) for testicular cancer at age 65 years or older (64.0% [59.3-68.7]), sarcoma of extremities (60.0% [58.9-61.2]), digestive-system endocrine cancers (55.6% [54.9-56.3]), anal squamous-cell carcinoma (53.1% [51.5-54.8]), and uterine sarcoma (43.5% [42.0-44.9]); low for carcinoma of adrenal-gland cortex (32.7% [28.3-37.2]) and bladder squamous-cell carcinoma (20.4% [18.8-22.0]); and poor for angiosarcoma of liver (6.4% [1.8-11.0]) and mesothelioma (4.7% [4.3-5.2]).
  • Survival significantly improved over time for ovarian germ-cell cancer, sarcomas of extremities, digestive-system endocrine tumours, anal squamous-cell carcinoma, and angiosarcoma of liver.

  • MedlinePlus Health Information. consumer health - Rare Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16455477.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


77. Ho KJ, Owens CD, Ledbetter SM, Chew DK, Belkin M: Renal venous diversion: an unusual treatment for renal vein thrombosis. J Vasc Surg; 2006 Jun;43(6):1283-6
MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This can usually be treated with systemic anticoagulation, and the diversion is via natural draining tributaries, eg, adrenal, lumbar, or gonadal veins.
  • Occasionally, renal venous thrombosis results from extension of a thrombotic process, such as a large renal cell carcinoma with tumor thrombus extension into the infrahepatic inferior vena cava resulting in thrombosis of the inferior vena cava and contralateral renal vein.

  • Genetic Alliance. consumer health - Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765255.001).
  • [ISSN] 0741-5214
  • [Journal-full-title] Journal of vascular surgery
  • [ISO-abbreviation] J. Vasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Amar L, Plouin PF, Steichen O: Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. Orphanet J Rare Dis; 2010;5:9
HAL archives ouvertes. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unilateral aldosterone hypersecretion is caused by an aldosterone-producing adenoma (also known as Conn's adenoma and aldosteronoma), primary unilateral adrenal hyperplasia and rare cases of aldosterone-producing adrenocortical carcinoma.
  • Its prevalence in referred hypertensive populations is estimated to be between 6 and 13%, of which 1.5 to 5% have an aldosterone-producing adenoma or primary unilateral adrenal hyperplasia.
  • The differential diagnosis of hypokalemic hypertension with low renin includes mineralocorticoid excess, with the mineralocorticoid being cortisol or 11-deoxycorticosterone, apparent mineralocorticoid excess, pseudo-hypermineralocorticoidism in Liddle syndrome or exposure to glycyrrhizic acid.
  • Once the diagnosis is confirmed, adrenal computed tomography is performed for all patients.
  • If surgery is considered, taking into consideration the clinical context and the desire of the patient, adrenal vein sampling is performed to detect whether or not aldosterone hypersecretion is unilateral.
  • It generally results in the normalization of aldosterone secretion and kalemia, and in a large decrease in blood pressure, but normotension without treatment is only achieved in half of all cases.
  • [MeSH-major] Adrenocortical Adenoma / diagnosis. Adrenocortical Adenoma / metabolism. Aldosterone / metabolism. Hyperaldosteronism / diagnosis. Hyperaldosteronism / surgery

  • Genetic Alliance. consumer health - Primary aldosteronism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Cardiol. 2005 Apr 19;45(8):1243-8 [15837256.001]
  • [Cites] J Urol. 2005 Jul;174(1):40-3 [15947573.001]
  • [Cites] Radiographics. 2005 Oct;25 Suppl 1:S143-58 [16227488.001]
  • [Cites] Surgery. 2005 Dec;138(6):1009-16; discussion 1016-7 [16360385.001]
  • [Cites] J Hum Hypertens. 2006 Feb;20(2):129-36 [16292348.001]
  • [Cites] Am Surg. 2005 Oct;71(10):864-9 [16468537.001]
  • [Cites] J Hypertens. 2006 Feb;24(2):371-9 [16508586.001]
  • [Cites] JAMA. 2006 Jun 14;295(22):2638-45 [16772627.001]
  • [Cites] J Am Coll Cardiol. 2006 Dec 5;48(11):2293-300 [17161262.001]
  • [Cites] Hypertension. 2007 Apr;49(4):846-56 [17296870.001]
  • [Cites] Hypertens Res. 2007 Feb;30(2):111-7 [17460380.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 May;66(5):607-18 [17492946.001]
  • [Cites] J Hypertens. 2007 Jul;25(7):1433-42 [17563566.001]
  • [Cites] ANZ J Surg. 2007 Sep;77(9):768-73 [17685956.001]
  • [Cites] J Hypertens. 2007 Sep;25(9):1751-62 [17762635.001]
  • [Cites] Ann Endocrinol (Paris). 2007 Oct;68(5):349-56 [17368420.001]
  • [Cites] Am J Hypertens. 2007 Dec;20(12):1334-7 [18047926.001]
  • [Cites] Surgery. 2007 Dec;142(6):921-9; discussion 921-9 [18063077.001]
  • [Cites] J Vasc Interv Radiol. 2008 Jan;19(1):66-71 [18192469.001]
  • [Cites] Arch Intern Med. 2008 Jan 14;168(1):80-5 [18195199.001]
  • [Cites] Ann Surg. 2008 Mar;247(3):511-8 [18376197.001]
  • [Cites] Endocr Rev. 2008 Apr;29(2):133-54 [18292466.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1366-71 [18198224.001]
  • [Cites] Hypertension. 2008 May;51(5):1366-71 [18347224.001]
  • [Cites] Lancet. 2008 Jun 7;371(9628):1921-6 [18539224.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Jul;69(1):20-8 [18284637.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jul;93(7):2454-62 [18413427.001]
  • [Cites] Horm Metab Res. 2008 Jul;40(7):435-41 [18493881.001]
  • [Cites] J Hypertens. 2008 Sep;26(9):1816-23 [18698217.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Sep;93(9):3266-81 [18552288.001]
  • [Cites] Chirurg. 2008 Nov;79(11):1087-94; quiz 1095-6 [18941729.001]
  • [Cites] Surgery. 2008 Dec;144(6):926-33; discussion 933 [19040999.001]
  • [Cites] Clin Endocrinol (Oxf). 2009 Jan;70(1):14-7 [19128364.001]
  • [Cites] Ann Surg. 2009 Feb;249(2):318-21 [19212188.001]
  • [Cites] Hypertension. 2009 Apr;53(4):605-10 [19221213.001]
  • [Cites] J Hum Hypertens. 2009 Apr;23(4):292-4 [18754018.001]
  • [Cites] Clin Chem. 2009 May;55(5):867-77 [19264850.001]
  • [Cites] Biomed Pharmacother. 2000 Jun;54 Suppl 1:164s-168s [10915016.001]
  • [Cites] Ann Intern Med. 2009 Sep 1;151(5):329-37 [19721021.001]
  • [Cites] Hypertension. 2010 Jan;55(1):83-9 [19933925.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):637-44 [10690869.001]
  • [Cites] Biomed Pharmacother. 2000 Jun;54 Suppl 1:83s-85s [10914999.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Mar;86(3):1066-71 [11238487.001]
  • [Cites] Am J Kidney Dis. 2001 Apr;37(4):699-705 [11273868.001]
  • [Cites] Ann Intern Med. 2001 Aug 21;135(4):258-61 [11511140.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4292-8 [11549664.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6762-7 [11559548.001]
  • [Cites] Am J Med Sci. 2001 Dec;322(6):302-7 [11780687.001]
  • [Cites] Metabolism. 2002 Mar;51(3):350-5 [11887172.001]
  • [Cites] Endocrinol Metab Clin North Am. 2002 Sep;31(3):619-32, xi [12227124.001]
  • [Cites] Am J Hypertens. 2002 Oct;15(10 Pt 1):896-902 [12372677.001]
  • [Cites] Hypertension. 2002 Dec;40(6):892-6 [12468575.001]
  • [Cites] Hypertension. 2002 Dec;40(6):897-902 [12468576.001]
  • [Cites] J Urol. 2003 Jan;169(1):32-5 [12478096.001]
  • [Cites] Nucl Med Commun. 2003 Jun;24(6):683-8 [12766605.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2489-94 [12788844.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Aug;88(8):3637-44 [12915648.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1045-50 [15001583.001]
  • [Cites] Endocr Rev. 2004 Apr;25(2):309-40 [15082524.001]
  • [Cites] Mol Cell Endocrinol. 2004 Mar 31;217(1-2):33-9 [15134798.001]
  • [Cites] Br J Surg. 2004 Oct;91(10):1259-74 [15376201.001]
  • [Cites] Arch Intern Med. 1981 Nov;141(12):1589-93 [7030245.001]
  • [Cites] Am J Cardiol. 1987 Oct 1;60(10):820-5 [3661395.001]
  • [Cites] J Hypertens Suppl. 1987 Dec;5(5):S103-6 [2832571.001]
  • [Cites] J Hum Hypertens. 1988 Oct;2(3):187-9 [3236322.001]
  • [Cites] Am J Hypertens. 1990 Jul;3(7):576-82 [2194512.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jul;75(1):323-7 [1619026.001]
  • [Cites] Surgery. 1992 Dec;112(6):987-93 [1455323.001]
  • [Cites] J Urol. 1993 Nov;150(5 Pt 1):1365-8 [8411401.001]
  • [Cites] Clin Radiol. 1994 Jul;49(7):453-5 [8088036.001]
  • [Cites] Clin Exp Pharmacol Physiol. 1994 Apr;21(4):319-22 [7923899.001]
  • [Cites] Ann Intern Med. 1994 Dec 1;121(11):877-85 [7978702.001]
  • [Cites] J Clin Invest. 1995 Nov;96(5):2236-46 [7593610.001]
  • [Cites] Radiology. 1996 Feb;198(2):309-12 [8596821.001]
  • [Cites] J Pediatr Surg. 1996 Mar;31(3):430-2 [8708918.001]
  • [Cites] Surgery. 1998 Dec;124(6):1128-33 [9854594.001]
  • [Cites] Lancet. 1999 Apr 17;353(9161):1341-7 [10218547.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):628-31; discussion 631-2 [10367872.001]
  • [Cites] Ann Intern Med. 1999 Jul 20;131(2):105-8 [10419425.001]
  • [Cites] J Lab Clin Med. 1955 Jan;45(1):3-17 [13233623.001]
  • [Cites] JAMA. 1964 Oct 19;190:213-21 [14246592.001]
  • [Cites] Lancet. 2005 Jan 15-21;365(9455):217-23 [15652604.001]
  • [Cites] Surgery. 2004 Dec;136(6):1227-35 [15657580.001]
  • (PMID = 20482833.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 4964P6T9RB / Aldosterone
  • [Number-of-references] 83
  • [Other-IDs] NLM/ PMC2889888
  •  go-up   go-down


79. Namboodiri N, Krishnamoorthy KM, Tharakan JA: Intra-atrial extension of Wilms' tumor. J Am Soc Echocardiogr; 2008 Jan;21(1):91.e3-4
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Echocardiography in a 4-year-old boy, with nephroblastoma of the left kidney, revealed a large homogenous mass in right atrium extending from inferior vena cava, and protruding through tricuspid valve into right ventricle during diastole.
  • Intracardiac extension of infradiaphragmatic tumors through caval route, although infrequent, can be seen with renal cell carcinoma, Wilms' tumor, hepatoma, lymphoma, and uterine and adrenal tumors.
  • [MeSH-major] Heart Neoplasms / diagnosis. Kidney Neoplasms / diagnosis. Wilms Tumor / diagnosis

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17628424.001).
  • [ISSN] 1097-6795
  • [Journal-full-title] Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
  • [ISO-abbreviation] J Am Soc Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Omura Y, Horiuchi N, Jones MK, Lu DP, Shimotsuura Y, Duvvi H, Pallos A, Ohki M, Suetsugu A: Temporary anti-cancer & anti-pain effects of mechanical stimulation of any one of 3 front teeth (1st incisor, 2nd incisor, & canine) of right & left side of upper & lower jaws and their possible mechanism, & relatively long term disappearance of pain & cancer parameters by one optimal dose of DHEA, Astragalus, Boswellia Serrata, often with press needle stimulation of True ST. 36. Acupunct Electrother Res; 2009;34(3-4):175-203
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One minute downward pressure on the tip of any one of the front 3 teeth (1st incisor, 2nd incisor, and canine) at the right and left sides of the upper and lower jaw by a wooden toothpick induced temporary disappearance (20 min approximately 4 hours) of abnormally increased pain parameters (pain grading, Substance P, & TXB2), and cancer parameters (Telomere, Integrin alpha5beta1, Oncogene C-fos Ab2, etc. of Astrocytoma, Glioblastoma, squamous cell carcinoma of esophagus, adenocarcinoma of lung, breast cancer, adenocarcinoma of colon, prostate cancer).
  • Above mechanical stimulation of one of these front teeth increased abnormally reduced DHEA levels of less than 10 ng to norm1 100 approximately 130 ng BDORT units and normal cell (NC) telomeres from markedly reduced values to near normal values, and improved acetylcholine in the Hippocampus.
  • Large organ representation areas for the Adrenal gland & Hippocampus may exist at these front teeth.
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Pain / diagnosis. Pain Measurement. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acupuncture.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20344885.001).
  • [ISSN] 0360-1293
  • [Journal-full-title] Acupuncture & electro-therapeutics research
  • [ISO-abbreviation] Acupunct Electrother Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down


81. Gaal J, de Krijger RR: Neuroendocrine tumors and tumor syndromes in childhood. Pediatr Dev Pathol; 2010 Nov-Dec;13(6):427-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endocrine and neuroendocrine cells form a large and diverse array of cell types.
  • They are present in the form of specialized organs, such as the pituitary, parathyroid, thyroid, and adrenal gland, or in the form of the diffuse neuroendocrine system in the respiratory and digestive tracts.
  • This review focuses on hereditary syndromes with neuroendocrine tumors, including multiple endocrine neoplasia types 1 and 2, Von Hippel-Lindau disease, neurofibromatosis type 1, Carney complex, pheochromocytoma-paraganglioma syndrome, and familial nonmedullary thyroid carcinoma.
  • In addition, several individual neuroendocrine tumors are described, such as medullary thyroid carcinoma, gastroenteropancreatic tumors, pheochromocytoma, and paraganglioma, emphasizing specific histopathologic characteristics.

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708762.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


82. Plaza JA, Perez-Montiel D, Mayerson J, Morrison C, Suster S: Metastases to soft tissue: a review of 118 cases over a 30-year period. Cancer; 2008 Jan 1;112(1):193-203
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors' experience was reviewed at a large academic medical center over a 30-year period (1971-2000) with metastases to soft tissue.
  • The primary tumor was located in the skin (19 patients), lung (13 patients), breast (13 patients), kidney (12 patients), colon and rectum (12 patients), uterus (8 patients), ovary (5 patients), head and neck (tongue, pharynx, larynx, nasal cavity, and mandible) (5 patients), esophagus (2 patients), stomach (2 patients), cervix (2 patients), small bowel (2 patients), bone (2 patients), adrenal gland (1 patient), eye (1 patient), testis (1 patient), urinary bladder (1 patient), and salivary gland (1 patient).
  • The histologic classification of the tumors included carcinoma (83 patients), malignant melanoma (20 patients), sarcoma and carcinosarcoma (9 patients), malignant mixed Mullerian tumor (2 patients), seminoma (1 patient), malignant teratoma (1 patient), malignant gastrointestinal stromal tumor (1 patient), and neuroblastoma (1 patient).
  • Many of the tumors displayed histologic features that created difficulties for diagnosis and could be easily mistaken on routine histopathologic examination for a variety of primary soft-tissue sarcomas.
  • Use of a basic panel of immunohistochemical stains is recommended for defining the cell type and arriving at the correct diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 American Cancer Society
  • (PMID = 18040999.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Marthya A, Patinharayil G, Puthezeth K, Sreedharan S, Kumar A, Kumaran CM: Multicentric epithelioid angiosarcoma of the spine: a case report of a rare bone tumor. Spine J; 2007 Nov-Dec;7(6):716-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is characterized by large cells with an epethelioid morphology.
  • EA has been reported in sites like skin thyroid, adrenal gland, soft tissue, and rarely in bone.
  • Immunohistochemistry showed positivity for endothelioid cell markers like CD31 and factor VIII related antigen.
  • The authors point out the need for immunohistochemical evaluation after careful histological analysis for vascular differentiation for an accurate diagnosis of vascular bone tumors with epithelioid features so that an erroneous diagnosis of metastatic carcinoma can be avoided.
  • EA is marked by the presence of large polygonal epithelioid malignant cells with marked cellular atypia and pleomorphism.
  • Careful histologic and immunohistochemical analysis will clinch the diagnosis.
  • Even though rare, we stress the importance to be aware of the existence of this tumor, which is essential for correct diagnosis.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998131.001).
  • [ISSN] 1529-9430
  • [Journal-full-title] The spine journal : official journal of the North American Spine Society
  • [ISO-abbreviation] Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Nadu A, Mor Y, Chen J, Sofer M, Golomb J, Ramon J: Laparoscopic nephrectomy: initial experience in Israel with 110 cases. Isr Med Assoc J; 2005 Jul;7(7):431-4
MedlinePlus Health Information. consumer health - Kidney Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraoperative complications were recorded in eight cases (7.3%), including vascular injuries of the renal artery in two, and of the renal vein, inferior vena cava and right adrenal vein in one case each.
  • Injury of the large bowel and splenic hylus was recorded in one case and malfunction of the vascular endoGIA stapler leading to severe bleeding in one case.
  • Histologic examination showed renal cell carcinoma pT1-T3a in 62 patients, oncocytoma in 5, transitional cell carcinoma T1G2-T3G3N1 in 10, renal sarcoma in 1, metastasis from lung tumor in 1, and end-stage kidney in the remainder.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Isr Med Assoc J. 2005 Aug;7(8):534
  • (PMID = 16011057.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


85. Roy PP, Basu N: Bilateral adrenal metastases from large cell carcinoma of lung in a female non-smoker patient. J Assoc Physicians India; 2006 Jun;54:504-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral adrenal metastases from large cell carcinoma of lung in a female non-smoker patient.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Carcinoma, Large Cell / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912999.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  •  go-up   go-down


86. Holland WP, Midthun DE: Massive adrenal metastasis. J Thorac Oncol; 2006 Feb;1(2):168
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive adrenal metastasis.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Carcinoma, Large Cell / secondary. Lung Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biopsy, Needle. Carboplatin / therapeutic use. Diagnosis, Differential. Female. Humans. Paclitaxel / therapeutic use. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409847.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement